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Abstract
Human herpesvirus-8, or KSHV, was discovered in 1994 and is the causative agent 
of all forms of Kaposi’s sarcoma (KS). It is also associated with two 
lymphoproliferative disorders: primary effusion lymphoma (PEL) and multicentric 
Castleman’s disease. The KSHV viral chemokine receptor, vGPCR, is a 
homologue of the IL8 receptors CXCR1 and CXCR2. vGPCR is considered a viral 
oncogene: it transforms fibroblasts in vitro and enhances growth and longevity of 
primary endothelial cells.
vGPCR signals promiscuously via several heterotrimeric G-protein subtypes and 
activates the MAP and SAP kinases, the Src family kinases, and PI3 kinase. 
However, little is known about vGPCR in the context of KSHV-infected 
haematopoietic cells. In this thesis, a tetracycline-inducible vGPCR-expressing PEL 
line is used to show that vGPCR causes a G0/G1 arrest in PEL cells via inhibition of 
Cdk2. This lack of Cdk2 function inhibits the chemically mediated KSHV latent-to- 
lytic switch. We hypothesize that expression of vGPCR outside of the normal lytic 
phase could inhibit virion production and resultant cell death; this would allow the 
many vGPCR-induced cytokines to have a more prolonged effect on the tumour 
microenvironment. These effects would result in enhanced angiogenesis, a hallmark 
of KS, as well as the recruitment of new infectable KSHV cells.
The vGPCR is among the most promising targets for rationally designed anti-KSHV 
therapy. However, a better understanding of vGPCR signalling events is required. 
This thesis also examines how vGPCR affects the function of the protein tyrosine 
phosphatases (PTPs), a family of enzymes that regulates many extracellular 
signalling events. PTPs are an exciting new potential target in anti-infective and 
anti-tumour therapeutics.
Lastly, we examine the inhibition of TGFp signalling by KSHV in PEL cells. PEL 
cells secrete TGFp but are resistant to its effects due to downregulation of TGFp 
Rll. This suggests a KSHV-mediated anti-immune strategy that requires further 
exploration.
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CHAPTER 1: INTRODUCTION
1.1 Overview
Kaposi’s sarcoma-associated herpesvirus (KSHV), or human herpesvirus-8 (HHV- 
8), was discovered in 1994 when two small fragments of its genome were detected 
in an AIDS-related Kaposi’s sarcoma (KS) lesion by representational difference 
analysis, a PCR-based subtractive hybridization technique (49). Since then, KSHV 
has been found invariably in KS lesions of all four epidemiologic types, and infection 
with KSHV has been shown to precede and predict the development of KS in HIV- 
infected patients (28, 51, 73, 281). KSHV is a y-2-herpesvirus and the first member 
of the genus Rhadinovirus known to infect humans. Epstein-Barr virus is its closest 
related human pathogen but several related primate and murine viruses have also 
been studied (see Fig 1.1). Consistent with the lymphotropic nature of y- 
herpesviruses, KSHV has also been found in lymph nodes, peripheral blood B cells, 
and is present in all forms of a subset of NHL called primary effusion lymphoma 
(PEL)(44). PEL is a rare malignancy occurring primarily, but not solely, in patients 
with AIDS and account for 3% to 5% of AIDS-related NHL (186). It is characterized 
by malignant effusions frequently without solid tumor masses, tends to occur late in 
HIV infection, and portends high morbidity and mortality. KSHV is also highly 
associated with another B-cell proliferative disorder called multicentric Castleman’s 
disease (MCD). This systemic form of Castleman’s
16
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Figure 1.1 Phylogenetic tree of KSHV and related herpesviruses. 
Neighbor-joining protein distance tree for the 142 amino acid residues 
encoded by the 426-bp fragment of DNA polymerase. The branch lengths 
are proportional to the evolutionary distance between the taxa.
From deThoisy et al, J Virol. 2003 Aug;77(16):9099-105
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disease presents with generalized lymphadenopathy, fever, lethargy, and 
immunological abnormalities. Furthermore, it has been shown that patients with 
MCD are at increased risk of B-cell lymphomas and KS (211).
Although KS, PEL and MCD can occur in its absence, HIV is a risk factor for 
all three proliferative disorders. Seroepidemiologic evidence shows that KSHV 
infection alone is not sufficient to cause disease, and that HIV infection or other 
non-HIV co-factors must be present (131). A satisfying description of the 
pathogenesis of KSHV-mediated disease is not yet complete but great progress has 
been made recently. The role of KSHV is gradually being clarified as are the 
similarities between HIV and non-HIV risk factors that allow KSHV infection to 
cause disease.
1.2 Kaposi’s Sarcoma
In 1872, a Hungarian dermatologist named Moriz Kaposi reported several cases of 
a multifocal pigmented sarcoma in elderly Viennese men. These purplish cutaneous 
lesions occurred sporadically and were typically on the lower extremities. All the 
patients described by Kaposi eventually died of what is now known as “classic” 
Kaposi’s sarcoma (KS). For unclear reasons, the disorder predominantly affects 
older men of Mediterranean and eastern European descent. Since Kaposi’s initial 
description, three more forms of KS have been identified. The second has been 
known in Africa for decades. “Endemic-African” KS is much more aggressive than 
classic KS and typically involves lymph nodes rather than skin. It has a high 
mortality rate, often affects HIV-negative hosts, and targets the young (300). A
18
third, iatrogenic form of KS occurs within a few months of solid organ transplant in 
patients on immunosuppressive medications. Although most common in transplant 
patients on cyclosporin, it has been known to occur in those on corticosteroids. Like 
classic KS, this form is more common in those of Mediterranean ancestry (59, 88).
A fourth and very aggressive type of KS was described in the early 1980s in 
otherwise healthy homosexual men (89). Along with Pneumocystis carinii 
pneumonia, this new form of KS heralded the onset of the AIDS epidemic and 
became the most common AIDS-related malignancy. AIDS-KS involves not only 
skin and lymph node, but often disseminates to the lung, gastrointestinal tract, liver 
and spleen. Early in the epidemic, lifetime incidence of KS in gay men was around 
50%. The incidence started to decline in the 1980s and then more precipitously 
with the introduction of effective HIV therapy in the late 1990s (150).
The histogenesis of the KS spindle cell has not been easy to trace. Although 
KS cells stain for certain endothelial cell markers like CD34 and factor VIII, some 
studies show that they express proteins similar to dendritic cells, macrophages or 
smooth muscle cells (261). It is debated therefore whether KS cells represent a 
heterogeneous population of cells or instead arise from a pluripotent mesenchymal 
precursor cell. More recent cell surface marker studies suggest that spindle cells 
may be of lymphatic endothelial cell origin (129, 279).
Another area of controversy involves whether KS represents a clonal, 
neoplastic process or a polyclonal inflammatory lesion. In early KS lesions, the 
spindle cell is low in number compared to the surrounding inflammatory cells. 
Furthermore, KS cells in culture are dependent on exogenous growth factors and
19
when implanted into nude mice can induce an inflammatory and angiogenic 
reaction, but do not induce tumors, as would fully transformed cells (232). 
Moreover, regression of KS can happen spontaneously or when 
immunosuppression is corrected. Such characteristics along with the multifocality 
of KS lesions argue that the process is primarily one of dysregulated inflammation. 
Confusing the picture, however, X chromosome inactivation studies within single 
lesions as well as comparisons of multiple lesions from a single patient support a 
clonal origin in a subset of advanced cases (219). More recent studies have shown 
varying monoctonality, oligoclonality and polyclonality from lesions of various 
patients (102). Furthermore, three neoplastic cell lines have been established from 
KS lesions (20). As discussed later, one possibility is that KS starts as a 
hyperplastic polyclonal lesion that later gives rise to a clonal cell population only 
under specific circumstances and selective pressures. KS may be similar to post­
transplantation lymphoproliferative disorders, which are EBV-driven B cell 
proliferations that may progress from a polyclonal hyperplasia, to monoclonal 
tumors with no evident genetic abnormalities, to frank malignant lymphomas with 
oncogene and tumor suppressor gene alterations (43, 140).
In 1994, Chang and colleagues used representational difference analysis 
(RDA) to detect two novel DNA sequences from a KS specimen that were present 
in much tower copy number in undiseased tissue from the same patient (49). The 
technique had not yet been used to find new viruses but in this case the isolated 
sequences showed 30-50% amino acid homology to known gamma herpesviruses 
including EBV. The association of KSHV with KS became stronger as multiple
20
investigators found KSHV sequences in virtually 100% of lesions of all four 
epidemiologic forms. KSHV could not, however, be propagated in culture from KS 
lesions and it took the establishment of PEL cell lines (see below) harboring the 
virus in latent form to make further seroepidemiologic studies possible (47).
1.3 Epidemiology of KSHV Infection
Of the many criteria for establishing KSHV as an etiologic agent of KS, some 
require an epidemiologic approach. There are numerous serologic assays to detect 
anti-KSHV antibodies using PEL cell lines as a source of latent or lytic antigen; the 
latter requiring chemical induction of viral replication. Immunofluorescence assays 
(IFA) to detect serum antibody to a viral latent nuclear antigen (LNA) have become 
the most commonly used (131). Although far from perfect, these assays are a great 
improvement over the previous PCR-based methods and allow more reliable 
comparison of various KS risk groups to each other and to control populations.
Other serologic assays have included immunoblotting and ELISA using whole virus 
or recombinant viral antigens (159).
In the United States, the seroprevalence of KSHV in the general population is 
likely between 5% and 10%. In gay, HIV-positive men the seroprevalence is 30%, 
and in HIV-positive women and hemophiliacs, prevalence is 3-4% (94). In parts of 
Africa, where KS is a much more common disease and often affects HIV-negative 
hosts, seroprevalence may be 25-50% in the general population and appears to 
increase with age (201). These findings correlate well with the incidence of KS in
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the same groups. Interestingly, using IFA to multiple lytic and latent KSHV antigens 
derived from a stimulated PEL cell line, some investigators claim a much higher rate 
of KSHV in several groups tested. Lennette et al. found 90% of American 
homosexual men to be seropositive as well as 25% of healthy blood donors and 2- 
8% of children (154). Regardless of discrepancies among different studies in 
seroprevalence rates, all of them indicate that KSHV infection is not ubiquitous, and 
that KS is not as prevalent as KSHV seropositivity. Together, these conclusions 
indicate that if KSHV is necessary for developing KS, it is certainly not sufficient.
Even supported by the pathologic evidence discussed above, population- 
based studies showing that KSHV seroprevalence and KS disease overlap do not 
prove a causal relationship between KSHV and KS. If KSHV infection is a 
necessary element in KS pathogenesis, then at some point infection must precede 
the full development of disease. Indeed, multiple comparisons of patients with KS, 
those at risk of KS, and HIV-negative control groups have shown that KSHV 
sequences in peripheral blood predict the development of KS (180). One well 
controlled study in particular used the same tissue type (i.e. peripheral blood 
mononuclear cells) to look for KSHV sequences in AIDS-KS patients and controls 
over time. KSHV could be detected prior to KS development in 52% of those who 
eventually manifested KS but in only 9-13% of controls (180). The presence of anti- 
KSHV antibody is another approach to establish prior infection. One group followed 
forty HIV-positive patients for up to eight years to show that KSHV seroconversion 
preceded KS in a high proportion of AIDS-related KS (94). Martin et al. studied 400 
HIV-positive men and found that anti-LNA seropositivity was independently
associated with subsequent KS. Anti-LNA antibody was present at baseline in 38% 
of men reporting any homosexual activity and in none of the strictly heterosexual 
men in the control group. Seropositivity directly correlated with a personal history of 
sexually transmitted disease and with number of sex partners. In all, the lifetime 
probability of developing KS in men who were both HIV and KSHV positive was 
50% (168).
1.4 KSHV Transmission
Although methods of detecting KSHV infection vary in accuracy, it is clear 
that groups at risk of KS always have a higher incidence of KSHV infection than 
their respective controls. The absolute numbers may not be perfectly accurate, but 
it appears that KSHV infection is not as wide spread in the general population as 
are some other human herpesviruses. Epidemiologic studies have argued for a 
sexual route of KSHV transmission within some risk groups, but unfortunately, a 
detailed understanding of transmission is still lacking.
As noted above, KSHV seropositivity does correlate with number of sexual 
partners in gay men (168). Precisely which sexual practices are riskiest is 
unknown. KSHV DNA has been detected in the saliva and oral tissues of 
seropositive patients, in the semen of AIDS-KS patients, and in the gastrointestinal 
mucosa from HIV-infected patients (82, 115, 269, 281). Virus shed in semen would 
not likely explain all transmission in either Classic-Mediterranean or endemic-African
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KS, but transmission via saliva may explain infection in some non-HIV groups. 
Indeed, the linear increase in KSHV seropositivity with age reported in Zambia by 
Olsen et al argues for a horizontal, non-sexual mode of transmission (201, 235). 
Other studies in Uganda and Zambia document KSHV infection in infants less than 
1 year old and argue for early horizontal rather than vertical transmission (300). 
There has been documented KSHV transmission via organ allograft, but most 
iatrogenic KS patients are likely KSHV infected prior to immunosuppressive therapy 
(221).
1.5 Primary Effusion Lymphoma
Malignant lymphomas are the second most common HIV-associated neoplasm and 
having AIDS-related KS is a known risk factor (21). Most AIDS-related lymphomas 
are B-cell NHLs. Of these, approximately 40% are Burkitt or Burkitt-like (BL), 30% 
are large cell (LCL), and 30% are large cell immunoblastic lymphomas (IBL) (139). 
Several less common AIDS-related NHL have also been described, including cases 
of malignant lymphoma occurring as body cavity effusions with other distinguishing 
features, such as a null cell phenotype and presence of EBV (110, 140). Homology 
with other lymphotropic herpesviruses prompted some to study both AIDS and non- 
AIDS related lymphomas and led to the observation that KSHV DNA was detectable 
only in lymphomatous effusions (47, 49). These studies suggested that KSHV- 
associated lymphomas represent a distinct diagnostic entity, called body cavity- 
based lymphoma (BCBL) or, more recently, primary effusion lymphoma (46). This 
malignancy accounts for 3% to 5% of AIDS-related NHL and has a unique set of
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morphological, immunophenotypic and molecular genetic characteristics that 
distinguish it from other AIDS-related NHL.
Clinically, PEL is an aggressive lymphoma that grows in liquid phase and has 
a predilection for spreading along serous membranes without an infiltrative or 
destructive growth pattern. Spreading throughout pleura, pericardium and 
peritoneum can sometimes be so extensive as to make the site of origin 
undeterminable at autopsy. These malignant effusions occur largely without 
associated solid tumor or mass, hence the term ‘primary ’effusion lymphoma as 
distinct from the common effusions complicating many types of NHL. However, 
approximately 15% of KSHV-associated lymphomas in HIV-positive patients 
present as solid extranodal tumors, with about half of these developing a 
subsequent lymphomatous effusion. Histologically, the most common appearance 
of PEL is a large mixture of immunoblast-like cells along with other anaplastic, 
multilobulated or multinucleated cells resembling the Reed-Sternberg cells of 
Hodgkin’s disease. Numerous mitotic figures are present and there is evident 
necrosis of some tumor cells with subsequent lysis and disintegration to form 
granular background material (186).
In addition to KSHV infection, there are other interesting genetic features of 
PEL. Co-infection with EBV is common and usually clonal, but interactions between 
EBV and KSHV are not yet clear. PEL tumors lack c-myc gene rearrangements 
and most also lack bcl-2, ras, and p53 alterations (45). While the vast majority of 
tumors have a B-cell genotype, tumor cells usually do not express B- and T-cell 
associated antigens, although they do display various markers of activation such as
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CD30, CD38, and CD71 (11). PEL-derived cells in culture retain the KSHV genome 
as a large nuclear episome at 40-80 copies per cell (47). Typically, these cells are 
of clonal origin and are transformed by standard criteria (91, 231). KSHV gene 
expression in PEL cell lines is consistent with latent infection in which lytic genes 
necessary for viral replication are expressed in only a small proportion of cells (84).
The epidemiology of PEL correlates with the distribution of KSHV infection. 
Most cases have been found in men, frequently HIV-infected with homosexuality as 
a risk factor. Similar to KS, the median age of PEL onset is younger in AIDS-related 
cases.
1.6 Multicentric Castleman’s Disease
At this writing, the only other AIDS-related disease that is convincingly
associated with KSHV infection is multicentric Castleman’s disease (MCD) (203). 
Although Castleman’s disease (CD) was originally described as a localized 
lymphoid hyperplasia, MCD was later described as a systemic variant (90). AIDS 
patients are particularly prone to this systemic form and although there is histologic 
overlap, MCD is more often of the plasma cell type than the hyaline-vascular type of 
CD usually seen in localized disease. MCD is found more often in men than women 
and incidence increases with age. Patients develop multiple lymphadenopathies 
and a variety of constitutional symptoms. Cytopenias, rashes and intercurrent 
infections are not unusual. Interestingly, some patients with MCD have been 
reported to develop NHL. Additionally, the plasma cell histologic type of MCD is a 
risk factor for KS (253).
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The combination of pathologic evidence and epidemiologic associations with 
other KSHV-related disease argues a strong case for KSHV as an etiologic agent in 
MCD. Soulier et al looked for KSHV DNA sequences in samples from 31 
Castleman’s disease patients and found evidence of infection in all 14 of those with 
concomitant HIV infection but in only 7 of the 17 HIV-negative subjects (253). 
Further work showed that KSHV is found almost universally in HIV-associated MCD 
specimens but in only 40% of immunocompetent hosts with MCD (17, 73). 
Moreover, the intensity of KSHV viral load in peripheral blood seems to correlate 
directly with worsening symptoms and poorer prognosis in MCD patients (109).
1.7 Kaposi’s Sarcoma-Associated Virus
1.7.1 Structure and Classification
The establishment of various PEL-derived cell lines that harbor KSHV has been 
pivotal in characterizing the virus. Based on genetic comparison of its major capsid 
protein, KSHV has been classified as a y-2-herpesvirus, the first herpesvirus of the 
genus Rhadinovirus known to infect humans (231). As demonstrated by EBV and 
herpesvirus saimiri (HVS), the y-herpesviruses have a predilection for infecting 
lymphocytes. EBV is well known to immortalize B-cells in vitro and is linked to 
AIDS-related lymphomas, endemic Burkitt’s lymphomas, post-transplant 
lymphoproliferative disorders and Hodgkin’s disease (73). HVS, a simian 
rhadinovirus, causes T cell lymphomas and can immortalize T cells in vitro. As 
discussed, KSHV is associated PEL and MCD, both lymphoproliferative diseases.
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The family Herpesviridae has been divided into three subfamilies: 
Alphaherpesvirinae, Betaherpesvirinae , and Gammaherpesvirinae (226, 228). The 
original classification was based on biological criteria and although quite good at 
predicting the relatedness of different herpesvirus species, herpesvirus taxonomy 
now relies on sequence information that provides solid data on gene organization 
and arrangement. The subfamily Alphaherpesvirinae includes human herpesvirus 
simplex type 1 and 2 (HSV-1, HSV-2) and varicella-zoster virus (VZV). These 
viruses have a short reproductive cycle, establish latency in sensory ganglia , and 
spread rapidly in culture. Betaherpesviruses include human herpesvirus 6 and 7 
(HHV-6,HHV-7) and human cytomegalovirus (HCMV); they are characterized by 
slower spread in culture, a longer replicative cycle, and establish latency in 
lymphoreticular cells. The human gammaherpesviruses include Epstein-Barr virus 
(EBV) and Kaposi’s sarcoma-associated herpesvirus (KSHV). Generally, 
gammaherpesviruses have a very narrow host range and establish latency in 
lymphoid cells. Many of them will replicate in vitro in lymphoblastoid cells (227).
Herpesviruses all share structural features such as a linear double-stranded 
DNA genome, an icosadeltahedral capsid surrounded by an amorphous tegument, 
and a glycoprotein-rich envelope. Human herpesviral genomes range in size from 
125kbp (65) to 230kbp (53). However, individual herpesvirus isolates may vary in 
genome size due to the number of internal or terminal repeat sequences. These 
repeats can also give rise to various genomic isomers (see Figure 1.2A). The HSV 
and HCMV genomes contain two sets of inverted repeats giving rise to four possible 
isomers depending on the orientation of the unique long (UL) and unique short (US)
sequences. VZV contains an internal repeat in opposite orientation to the terminal 
repeat, allowing two genomic isomers. The EBV and KSHV genomes contain direct 
terminal repeats and EBV also has smaller internal repeats. Within the herpesvirus 
genomes, seven blocks of conserved genes have been described and labeled the 
“herpesvirus core” that defines the herpesviruses as a family (53) (Figure 1,2B).
This conserved core is generally located in the center of most of the human 
herpesviruses (53, 66). The seven blocks are not collinear between viruses but 
within the blocks the genes are homologous and collinear, although there is some 
divergence in gene number and relatedness. Many of the characteristic functions of 
herpesviruses are determined by products of the core genes, with the striking 
exception of the latency-associated genes which are not even conserved among the 
subfamilies.
As mentioned above, sequence data show that KSHV is a gamma-2- 
herpesvirus and as such is a member of the rhadinovirus subgroup of herpesviruses 
(26, 49, 193, 231). Like the “prototypic” rhadinovirus of New World primates, 
herpesvirus saimiri (HVS), the KSHV genome contains a central segment of low- 
GC DNA (L-DNA) that is flanked by repetitive high-GC DNA (H-DNA). The terminal 
repeats (TR) are tandem repeats of an 801 bp H-DNA sequence (86% GC). The L- 
DNA contains over 80 open reading frames (ORFs); again like HVS, many of these 
encode unspliced homologues of host cell genes suggesting acquisition of host 
cDNA . Herpesviruses in general have done well at acquiring host genes, but the 
rhadinoviruses are particularly good pirates. Cellular homologues encoded by the 
rhadinoviruses generally function in immune evasion, nucleotide metabolism and
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cell growth. Unlike other subfamily members, KSHV also encodes viral versions of 
IL-6, three CC chemokines, and interferon response factors (Figure 1.3). Although 
each rhadinovirus has acquired a slightly different subset of host genes, there is 
strong positional similarity with cellular homologues particularly prevalent near the 
genomic termini (for review see (194)).
KSHV has been further subclassified based on some of its more variable 
sequences. Zong et al described three strains, A, B, and C. Strain A was found 
more often in classic-Mediterranean KS, whereas B and C were found in African 
KS. Although strains B and C were found in AIDS-related KS cases in the U.S., 
most isolates from the east coast were nearly identical, leading the authors to 
postulate a common source. More recently, other investigators have described 
KSHV genotypes l-IV and found that those corresponding to types A and B of the 
earlier classification scheme are predominant in the U.S. There is no convincing 
evidence that specific strains are preferentially associated with disease type or 
severity (117).
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Figure 1.2 Genome structure of the human herpesviruses. A) HSV and HCMV both contain 2 
sets of inverted repeats that result in 4 possible isomers with respect to the orientation of the 
unique long (UL) and unique short (US) sequences. VZV contains a large internal repeat that is 
repeated at only one terminus, giving rise to 2 possible isomers. The y-herpesviruses EBV and 
KSHV have direct terminal repeats (TR) and in the case of EBV a set of internal repeats 
dividing the genome into UL and US sections. Both also have smaller internal repetitive 
sequences. Like all rhadinoviruses, KSHV has one long unique region (LUR) flanked by the 
direct TRs. Horizontal hatch represents direct repeats and diagonal hatch represents inverted 
repeats. B) Schematic of the KSHV genome; ORFs with homology to other herpesviruses are 
numbered while unique genes are prefaced with ‘K’. Some of the unique KSHV genes 
discussed in this thesis are also labelled with more descriptive names. The seven conserved 
herpesvirus core blocks are numbered as shown. Adapted from references (193 ,222 ,231 ). 
Introns not shown for clarity.
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Figure 1.3 Rhadinovirus genomes. KSHV, HVS, and herpesvirus ateles (HVA) 
genomes are orientated to align the core gene blocks. Cellular homologues are shown. 
(CCPH, complement control protein; vlL-6, viral interleukin-6; DHFR, dihydrofolate 
reductase; TS, thymidine synthase; bcl-2, viral bcl-2 homologue; IRF, interferon 
response factor; vGPCR, viral G protein-couple receptor; v-cyclin, viral homologue of 
D-type cyclins; vCCL-1,2,3, viral homologues of CC-type chemokines; gpcr-a/p, G 
protein-coupled receptor a /p .)  Adapted from Neipel etal, 1 9 9 7  (1 9 3 ). Genes are colour- 
coded for functional class.
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1.7.2 Selected KSHV Gene Products
As a herpesvirus, KSHV can establish latency with restricted gene expression in cell 
culture and in vivo. Carefully regulated transcription allows infecting viruses to 
manipulate the host cell to their replicative needs and to avoid certain host immune 
responses by limiting antigen processing and expression. Understanding KSHV 
gene expression patterns is key to understanding pathogenic mechanisms and 
developing effective therapies for its related diseases. Unfortunately, these patterns 
studied in vitro may not always accurately represent the various tumors in vivo. 
Additionally, tissue-specific differences in transcription patterns undoubtedly 
contribute to the very disparate clinical presentations of KSHV-mediated disease. 
Despite these inherent difficulties, work in this area has allowed some 
generalizations.
Class I gene transcripts, or latent genes, are present at baseline in 
uninduced PEL-derived cell lines and KS spindle cells. These include the following: 
a D-type cyclin homologue; a putative apoptosis inhibitor vFLIP; transcripts from the 
K12 region (kaposins) of poorly understood function; and the latency-associated 
nuclear antigen, LANA (234, 257, 299). Class II transcripts are those present in low 
copy at baseline but increase with chemical induction of PEL-derived cell lines. 
Among these are homologues of interleukin-6, interferon regulatory factor, a G 
protein-coupled receptor, and two CC-type chemokines. Class III genes, generally 
well conserved among herpesviruses, encode structural proteins and although not 
expressed during latent infection, are inducible in PEL cell lines (234). In KS tissue,
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only a small number of cells express Class II and III transcripts, representing lytic 
infection. The role of lytically infected cells in tumor maintenance and growth is 
debated. Furthermore, more detailed transcriptional analysis has shown 
complexities that while helping understand the pathogenic roles of various KSHV 
products, makes a simple class division of KSHV transcripts less tenable (263).
Many KSHV-encoded proteins certainly contribute to the pathogenesis of KS, 
PEL, and MCD. Some of the most suspicious are homologues of cellular genes 
involved in inflammation, cell cycle regulation, and angiogenesis. For example, 
KSHV encodes a homologue of the cellular D-type cyclins that is expressed in KS 
tumors and PEL cell lines (48). Like the cellular cyclin, the viral cyclin (vCYC) can 
activate kinases that phosphorylate and thereby inactivate pRB, a checkpoint 
protein that inhibits entry into S phase. Unlike its cellular counterpart, however, 
vCYC does not appear to be inhibited in the usual fashion, and can therefore 
sabotage a possible pRB-mediated defense against ongoing viral infection (264).
By manipulating the host cell cycle to allow its own maintenance, KSHV may also 
contribute to tumorgenesis as has been seen in other lymphoid malignancies 
associated with dysregulated D-cyclin expression (184).
Apoptosis of infected host cells is an immunologic strategy that viruses must 
elude if they are to establish persistent infection. KSHV encodes a homologue of 
the cellular bcl-2 family members that consist of various pro- and anti-apoptotic 
proteins (57). This viral bcl-2 (vbcl-2) contains crucial conserved domains for 
interaction with other bcl-2 members and has been shown to inhibit apoptosis in 
vitro (57). Expression of vbcl-2 in KS increases with lesion stage, and in culture is
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present at low levels during latent infection but can be chemically induced like other 
class II products (183, 236). Whether the role of vbcl-2 is solely to prevent 
apoptosis and allow viral synthesis is unclear. Its importance in the pathobiology of 
KS is supported, however, by clinical remission of KS after treatment with paclitaxel, 
a compound known to inhibit bcl-2 function (238, 280).
KSHV also encodes a FLICE-inhibitory protein (vFLIP) that may work to 
prevent TNFR-1 and Fas-mediated apoptosis. FLICE, or caspase-8, is a protease 
necessary for the apoptotic cascade used by the innate immune response to protect 
against viral infection. After apoptotic receptors such as TNFR-1 and Fas are 
activated, they bind via their death domains to intermediary proteins that 
subsequently bind and activate FLICE. FLIPs can also bind these intermediary 
proteins and hence compete with FLICE (286). Virally encoded FLIPs are found in 
other y-herpesviruses but their transcriptional control appears to vary from KSHV 
(237). The importance of this anti-apoptotic strategy to KSHV-related disease is 
under study.
Interferons mediate part of the innate immune response to viral infection. 
KSHV encodes homologues of the human interferon regulatory factors (IRF), 
transcriptional factors that modify interferon-mediated effects (231). In vitro, the 
KSHV-encoded vlRF1 is functional and can inhibit interferon signaling.
Furthermore, when stably transfected into fibroblast cell lines, vlRF1 can transform 
cells that in turn form tumors in nude mice (93). More recent work shows that vIRF 
can inhibit the anti-proliferative effects of interferon-a, again supporting a role in 
KSHV-mediated tumor formation (86). vlRF1 may also help regulate other viral
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genes, such as vlL-6 (156). Ongoing studies of the transcriptional control and 
expression in vivo of vIRF will allow better estimations of its role in KS, PEL, and 
MCD. To complicate matters, however, it is now known that three additional KSHV 
open reading frames encode factors homologous to the cellular IRFs (36).
Another KSHV protein with pathogenic potential is a homologue of human IL- 
6, a cytokine with many hematopoetic and immune response functions. IL-6 is a 
growth factor for EBV-transformed B cell lines and its dysregulation is associated 
with polyclonal plasma cell abnormalities (118). Furthermore, IL-6 has been linked 
to the development of Castleman’s disease (153). These properties make vlL-6 a 
suspicious player in the KSHV-related lymphoproliferative disorders. Indeed, KSHV 
vlL-6 expression is detectable in lymph nodes of KSHV-infected MCD patients and 
has been postulated to be partly responsible for the autoimmune complications 
found more often in such cases (206). Several groups have shown that vlL-6 is 
expressed to a much greater degree in PEL and MCD in situ than in KS lesions, 
implying a less prominent role for vlL-6 in KS relative to PEL and MCD (256)
Angiogenesis is important to any tumor growth and here again KSHV seems 
to have pirated some relevant cellular genes. Open-reading frame 74 of KSHV 
encodes a G protein-coupled receptor that is most homologous to the human 
interleukin-8 receptors, CXCR1 and CXCR2 (48). KSHV vGPCR is a more 
promiscuous receptor than its cellular homologue, as it signals constitutively in vitro, 
and can be further upregulated by several chemokines (9). When injected into 
mice, vGPCR-transfected rodent fibroblasts caused spindle cell tumors with 
prominent vasculature. The vGPCR was assessed specifically for angiogenic
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properties, and it was shown that medium conditioned by vGPCR-transfected cells 
could induce angiogenesis in human endothelial cells. Angiogenesis was mediated 
by vascular endothelial growth factor, a protein well established as a growth factor 
for KS (13). The function of the vGPCR is the primary subject of this thesis and is 
discussed in more detail in sections 1.9-1.11.
Other KSHV-encoded products that may contribute to angiogenesis in vivo 
are two homologues of human macrophage inflammatory proteins, vCCL-l and 
vCCL-ll (231). The vCCLs differ from human CCLs in that they are angiogenic in 
standard chick chorioallantoic assays (27). Interestingly, both vCCL-l and vCCL-ll 
can inhibit HIV cell entry in vitro, as can certain human chemokines. More recently, 
vCCL-ll has been shown to be an inhibitor of vGPCR (98). Why KSHV encodes an 
antagonist for its own GPCR is unclear but may prove to be an interesting aspect to 
the KSHV life cycle.
Aside from the above cellular homologues, KSHV encodes other genes that 
display potentially vital signaling and transforming properties. For example, the 
KSHV K1 gene occupies an analogous position to the HVS STP gene that is 
required for HVS-induced transformation. K1 can transform rat fibroblasts and 
when engineered to replace STP in HVS, the recombinant virus maintains the ability 
to cause lymphoma in marmosets (151). K1 has an ITAM motif that can activate 
cytoplasmic tyrosine kinases and mimic signaling by the B cell antigen receptor 
(151). KSHV K12, also known as kaposin, causes focal transformation when 
expressed in Rat-3 cells. Furthermore, these cells produce highly vascular, 
undifferentiated sarcomas when injected into athymic mice (185).
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As we can see, the list of KSHV genes that affect cell growth, proliferation, 
inflammation, and angiogenesis in vitro is long. Studies using monoclonal 
antibodies to examine protein expression are emerging, but more are required to 
determine which KSHV products are important in each KSHV-related disease.
Such studies may also explain the apparent functional redundancy within the KSHV 
genetic armamentarium.
1.8 Pathogenesis
Synthesizing what is known about KSHV and its pathogenic role in AIDS-related 
malignancies still requires a great deal of speculation. There are probably as many 
theories as investigators and many issues remain controversial. The complexity of 
these diseases is immediately apparent upon histologic examination of a Kaposi’s 
sarcoma lesion. Unlike most tumors, KS lesions harbor a variety of cell types 
including a mixture of inflammatory cells, endothelial cells and the characteristic 
spindle cell. And as discussed, the KS spindle cell frequently does not display a 
transformed phenotype, typically loses KSHV infection in culture, and is dependent 
on various growth factors and cytokines. Yet somehow, in the right immunologic 
setting, tumor growth ensues and KSHV infection persists.
There is evidence that even prior to acquiring KSHV infection, all patients at 
risk for KS show CD8* T-cell activation and increased levels of Th, cytokines, 
including IFNy (249). Ensoli et at have postulated that at least in the cases of 
African KS and AIDS-KS, those at risk may be under abnormally high chronic 
allogenic stimulation from recurrent infection (77). These same up-regulated
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cytokines such as IL-1, IL-6, TNF, and IFNy, are also produced within KS lesions 
and can cause endothelial cells to take on the KS spindle cell morphology (78). KS 
spindle cells in turn secrete factors that may act as autocrine or paracrine growth 
factors resulting in lesion expansion. For example, cytokine-induced spindle cells 
secrete bFGF and VEGF, which display autocrine and/or paracrine mitogenic 
effects, and act synergistically to induce angiogenesis, edema and KS-like lesions 
in animal models (76, 233).
There is little doubt that early KS is a cytokine driven event and that KSHV 
plays a central role. All early KS lesions contain KSHV, making KSHV appear 
necessary for KS lesion formation. Whether KSHV causes the inflammation 
present in KS lesions or, alternatively, is somehow recruited later to a pre-existing 
inflammatory lesion is still debated. Both circulating monocytes and B cells can 
harbor KSHV, and it has been recently shown that infection persists in culture in the 
presence of the same inflammatory cytokines that are up-regulated in at-risk 
patients (178). This raises the possibility that persistently KSHV-positive circulating 
cells, specifically monocytes, may carry KSHV to tissue lesions composed of 
activated endothelial cells and inflammatory cells that can support KSHV infection 
and spindle cell formation through the proper milieu of growth factors. Of note, 
lesional monocytes are more often lytically infected, perhaps producing viral gene 
products with potent paracrine effects. These infected monocytes may even be 
responsible for spreading progeny virus to other lesional cells (22). Such a 
sequence could explain the multifocality of KS. It may only be later in lesion
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development that the KSHV gene products discussed above act to accelerate 
angiogenesis and growth, eventually resulting in a true clonal tumor (77).
If all KS hosts display similar immunoactivation, it remains to be explained 
why the various forms of KS have different clinical presentations. For example, 
AIDS-KS is a much more aggressive form than Classic-Mediterranean KS. Part of 
the answer may lie in HIV-1-encoded Tat, a protein necessary to HIV-1 replication. 
In culture, extracellular Tat can cause IFNy-primed endothelial cells to grow, 
proliferate and differentiate, forming tube-like structures. These cells also secrete 
known angiogenic and tumor growth factors. Tat acts synergistically with bFGF to 
cause these effects in endothelial and KS spindle cells. Furthermore, when bFGF 
and Tat are inoculated together, they cause KS-like lesions in nude mice (75). In 
all, the evidence is strong that HIV-1 Tat is an important co-factor in KSHV disease; 
and as Gallo points out, this may explain why KS is rare in African populations 
where KSHV infection is common but HIV-2, rather than HIV-1, predominates (92).
The contribution of immunosuppression to the pathogenesis of KS-mediated 
disease is still difficult to assess. Part of the problem is that the normal immune 
response to KS is not yet understood, although some initial cytotoxic T-cell 
response studies have been done (204). Certainly not all KS risk groups show 
obvious immunosuppression, but subtle acquired or genetic defects may remain 
undiscovered. PEL on the other hand, occurs more frequently in late stage AIDS, a 
profoundly immunosuppressed condition, although cases do occur in HIV-negative 
individuals. Moreover, the advent of highly active anti-retroviral therapy appears to
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have decreased the incidence of KS and may be beneficially affecting the incidence 
and course of PEL.
Although KSHV infects B cells, what happens thereafter to result in the 
KSHV-related lymphoproliferative disorders is unclear. As discussed above, KSHV 
certainly shows potential to influence B-cell survival via vlL-6 and to counter IFN- 
mediated anti-proliferative effects via vIRF. However, the circumstances under 
which these proteins function in vivo are not known. For example, it is possible that 
more than one KSHV gene transcription program exists in latently infected 
lymphocytes. Furthermore, the mechanism of the switch from latent to lytic infection 
has not been worked out. Host immune surveillance may dramatically influence 
these transcription patterns and thus dictate the consequences of KSHV infection. 
Supporting a very important role for immunosuppression in KSHV-related disease, 
Min et al have shown that KSHV DNA increases in peripheral blood mononuclear 
cells (PBMC) of HIV-infected patients as CD4+cell count decreases (176). With 
rising viral load it is possible that KSHV-mediated lymphocyte proliferation 
increases. This may start to explain the aggressiveness of KSHV-positive MCD in 
HIV-positive patients. It would also be relevant to the development of PEL, a clonal 
malignancy that may arise from a background of vigorous B-cell proliferation (72).
A correlation between detectable KSHV DNA in PBMCs and immune 
surveillance may prove important in other ways as well. For example, it has not 
been ruled out that KSHV-mediated disease can result from viral reactivation. The 
possibility still exists that KSHV infection is much more common than suggested by 
the current detection techniques based on antigen expression and antibody
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development. It may be that KSHV detection in the infected immunocompetent host 
requires more sensitive techniques, and that both KSHV disease and viral 
detectability become more likely with immunosuppression.
1.9 G Protein-coupled receptors
Before discussing the KSHV vGPCR in more detail, I will quickly review some 
general principles of GPCRs. Also known as 7-transmembrane domain receptors 
or serpentine receptors, GPCRs are the largest family of signal-transducing 
molecules. There are approximately 747 human GPCRs including 350 olfactory 
receptors, 30 additional chemosensory receptors, and 367 other physiological 
receptors (274). By some accounts, GPCRs are the target of up to 30% of all 
clinically available medications with annual sales of $US 47 billion in 2003 (31, 101). 
Some examples are shown in Table 1.1.
The amino terminus of GPCRs is situated extracellularly while the carboxy 
terminus sits intracellularly. The seven a-helices span the cell membrane and make 
up the transmembrane bundle which is arranged in a tight barrel-like structure with 
a tightly packed core (Figure 1.4). The transmembrane regions support the three 
extracellular loops and an N-terminal segment that act as the cell surface receptor.
In addition to its topographical organization, post-translational modifications such as 
phosphorylation and glycosylation add to the structural complexity of GPCRs. 
Potential ligands include neurotransmitters, growth factors, hormones, calcium ions, 
and photons. Binding of ligand induces a relative shift in the positions of the 
transmembrane a-helices. Small ligands may bind within the transmembrane
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bundle, whereas larger ligands bind the amino termini and extracellular loops. 
Ligand-induced movement of the a-helices causes conformational changes of the 
intracellular loops that activate the heterotrimeric GTP-binding (G) protein. An 
‘agonist’ is a ligand that binds a receptor and shifts the receptor’s equilibrium 
towards the activated state. An ‘inverse agonist’ is one that pushes a constitutively 
active receptor towards an inactive state, while an ‘antagonist’ reduces the action 
of any other ligand by inhibiting the orthosteric or primary binding site. Antagonists 
are further subdivided into surmountable and insurmountable; the former 
participates in competitive and reversible antagonism. The latter either participate 
in irreversible competition at the binding site, non-competitive antagonism, or 
indirect antagonism (195). Once the receptor-agonist complex occurs, changes in 
receptor conformation activate the associated G protein(s) which exchanges GDP 
for GTP and splits into two separate signaling effectors: the a-subunit and the P y- 
subunit. There exist about 20 different a-subunits, 5 p-subunits, and 13 y-subunits 
in the mammalian system (149). While inactive, GDP is bound to the a-subunit and 
the py-subunit stabilizes this conformation by binding tightly to the Ga-GDP 
enhancing the coupling of the inactive heterotrimer to the associated GPCR. Upon 
activation however, GDP release is greatly accelerated over the slow baseline rate 
and GTP replaces GDP. Both the a-subunit and the Py complex have the capacity 
to regulate effector pathways such as phospholipase C (PLC), ion channels, or 
adenylyl cyclase (for review, see (285)). Normal G proteins contain an intrinsic 
GTPase activity that converts GTP back to GDP, resulting in reassembly of the a 
and Py subunits (Fig 1.5).
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Table 1.1 Examples o f Prescription Drugs that Target GPCRs
Brand Name Generic Name GPCR (s) Indication
Claritin loratidine
Zyprexa olanzapine
Risperdal risperidone
Cardura doxazosin
Tenormin atenolol
Zantac ranitidine
Cytotec misoprostol
Imigran sumatriptan
Serevant salmeterol
Imodium loperimide
Zoladex goserelin
Duragesic fentanyl
Cozaar losartan
Atrovent ipratropium
histamine 
serotonin 5-HT2 
and Dopamine 
serotonin 5-HT2 
a-adrenoceptor 
pr adrenoceptor 
histamine H2 
prostaglandin 
PGE1 
serotonin 5- 
HT 1b/1d 
p2-adrenoceptor 
opioid 
gonadotrophin- 
releasing factor 
opioid 
angiotensin II 
muscarinic
rhinitis/allergies
anti-psychotic
anti-psychotic 
prostate hypertrophy 
hypertension 
peptic ulcer
ulcer
migraine
asthma
diarrhea
prostate cancer
pain
hypertension
COPD
Adapted from McMurchie and Leifert, 2006
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Figure 1.4. Cross-eyed stereoscopic view of sensory rhodopsin II 
from Natronobacterium pharaonis. Edman etal, 2002. PDB: 1 
GUE. Image created with KiNG (http://kinemaoe.biochem.duke.eduy 
3-D image of sensory rhodopsin II is shown as a representative GPCR. 
Cross your eyes, relax your vision until there are three images, then 
focus on the center image.
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Agonist
GTP
Figure 1.5 Schematic of GPCR activation. Upon ligand binding, the GPCR  
changes conformation and promotes release of GDP from the heterotrimeric 
G-protein and rapid exchange with GTP into the nucleotide binding site on 
the G a subunit. The G-protein then dissociates into G a and G(3y subunits 
which interact with various downstream effectors. The signal is terminated 
by the spontaneous GTPase activity of the G a subunit which hydrolizes 
GTP to GDP. (Pi, inorganic phosphate; GDP, guanosine diphosphate; GTP, 
guanosine triphosphate; GPCR, G-protein coupled receptor) Adapted from 
R. Seifert, Nat Rev 2004 (242)
Agonist
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In addition to G-proteins, GPCRs interact with other proteins that dictate receptor 
localization, trafficking, and ligand binding properties. For example, some GPCRs 
have been shown to form receptor dimers which may affect agonist recognition and 
G-protein interactions but the role of dimerization is largely unresolved (23).
Another group of GPCR-interacting proteins is the G-protein receptor kinases 
(GRKs). These proteins participate in GPCR desensitization by inducing a rapid 
agonist-induced desensitization of the receptor by C-terminal phosphorylation (240). 
Once phosphorylated, the arrestins bind to the GPCR, preventing G-protein 
coupling and then target the GPCR to clathrin-coated vesicles for endocytosis (I.e. 
GPCR internalization) (155). Arrestins associate with GPCRs near the third 
intracellular loop (116).
1.10 The KSHV G protein-coupled receptor
During its co-evolution with its human host, KSHV has acquired many homologues 
of human genes involved in cell cycle regulation, angiogenesis, and inflammation 
(50, 57, 193, 231, 264, 286). KSHV vGPCR has the potential to affect all these 
processes. vGPCR has been characterized variably as an early or immediate early 
gene and is part of a bicistronic message that encodes K14/vOX-2 at its 5’-end 
(135, 187). (Cellular OX-2 or CD200 is expressed on the surface of many cell types 
and is postulated to provide an immune tolerizing signal. The role of vOX-2 is still 
unclear; for review, see (222)). The implications of vGPCR as a lytic gene will be 
discussed forther below. Like ORF 74 of murine gammaherpesvirus 68, KSHV 
vGPCR is a constitutively active variant of the human IL-8 receptors CXCR1, and
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CXCR2, as well as herpesvirus saimiri ECRF3 (2, 9, 48, 111, 277). vGPCR was 
first shown to have oncogenic potential in fibroblasts, but later work also proved that 
vGPCR could immortalize human umbilical vein endothelial cells (HUVEC) and 
protect them from serum deprivation (13, 62, 179). In vivo, KSHV infects cells of 
endothelial and hematopoietic origin. Signaling molecules can have very different 
effects depending on the cellular context, so these initial studies in endothelial cells 
were important in establishing vGPCR as a vital component of KSHV-mediated 
cellular proliferation.
KSHV vGPCR can influence the expression of various cytokines involved in 
the biology of KS and primary effusion lymphoma. For example, KS depends on 
vascular endothelial growth factor (VEGF) for its highly vascular morphology and 
KS spindle cells secrete and respond in an autocrine manner to VEGF (169, 233). 
Sodhi, et al. show that vGPCR mediates VEGF secretion by stimulating 
transcription factor hypoxia-inducible factor (HJF)-1 a in fibroblasts (252).
Conditioned medium from vGPCR-expressing fibroblasts in turn stimulates 
endothelial cell growth and the switch to an angiogenic phenotype (13). A 
fascinating study by Bais et al. in HUVECs shows that vGPCR induces 
immortalization with constitutive VEGF receptor-2/ KDR expression and activation. 
This was associated with anti-senescence mediated by alternative lengthening of 
telomeres and an anti-apoptotic response (14). vGPCR expression also increases 
VEGF production from hematopoietic cells (37); this is significant in that VEGF is 
essential for PEL tumor growth and ascites production in mice and furthermore 
contributes to a more aggressive phenotype of MCD (6, 7, 197).
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In addition to VEGF, vGPCR induces the expression of many pro- 
inflammatory cytokines important in KSHV-mediated disease. The monocytic line 
THP-1 expresses IL-1p, TNFa, and IL-6, and Jurkat cells elaborate IL-2 and IL-4 
when transfected with vGPCR (241). In PEL cell lines, vGPCR upregulates KSFIV 
vlL-6, an important growth factor in PEL and MCD (5, 127, 161). In endothelial 
cells, vGPCR upregulates the NFKB-dependent inflammatory cytokines RANTES, 
IL-6, IL-8, and granulocyte-macrophage colony-stimulating factor (GM-CSF). It also 
induces expression of the adhesion molecules VCAM-1, ICAM-1, and E-selectin. In 
the same study, supernatants from transfected KS cells activated NF-kB signaling 
in untransfected cells and caused the chemotaxis of monocytoid and T-lymphoid 
cells (208). This suggests that vGPCR may help recruit hematopoietic cells that 
make up the inflammatory component of KS lesions.
Although it is directly transforming in fibroblasts, and perhaps responsible for 
an immortalizing autocrine loop in endothelial cells (9, 13, 14), the ability of vGPCR 
to cause such robust and broad cytokine activity argues for an important paracrine 
role in KSHV-mediated disease. This is supported by the first vGPCR mouse model 
in which vGPCR was transcribed under the CD2 promoter (primarily T cell) and 
resulted in multicentric, angioproliferative lesions histologically similar to KS (291). 
The lesions ranged from erythematous maculae to vascular tumors; they contained 
spindle and inflammatory cells, expressed CD34, and VEGF. Despite causing 
endothelial cell tumors, vGPCR was expressed from relatively few infiltrating T cells.
KSHV vGPCR signaling may help explain why AIDS-associated KS is a more 
aggressive tumor than classic or iatrogenic KS. It has been known for several years
49
that the HIV-1 transactivator protein, Tat, activates KS cell growth and contributes 
directly to KS pathogenesis (16, 39, 74). Pati et al. have recently shown that HIV-1 
Tat and vGPCR synergistically activate the transcription factor NFAT. In turn, NFAT 
activation is responsible for production of IL-2, IL-4, GM-CSF, and TNF-* as well as 
expression of ICAM-1, CD25, CD29, and Fas ligand by the T cell line HUT 78 
(209). The expression of these surface molecules and inflammatory cytokines 
results in increased endothelial cell- T cell adherence and has important 
implications for vGPCR as a key molecule in the interaction between KSHV and 
HIV-1. Indeed, later work by the same group confirmed that HIV-1 Tat increases 
activation of NFkB and NFAT, and accelerates tumor formation in mice that are 
implanted with a cell line derived from a vGPCR transgenic mouse (112).
1.11 KSHV vGPCR Signaling and Function
1.11.1 Introduction
The signaling cascades vGPCR utilizes to effect changes in viral and host cell 
transcription are varied and in some cases cell-type specific. Despite increased 
understanding of its signaling potential, correlating these findings with biologic 
significance remains more problematic. In this section we will discuss what is 
known about the structure of vGPCR vis-a-vis its constitutive activity; the diversity of 
vGPCR signaling; as well as the potential roles in KSHV-mediated disease 
attributable to this unique receptor.
1.11.2 Multiple Ligands and Many Signaling Cascades
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KSHV vGPCR is in the rhodopsin/p2-andrenergic subfamily of GPCRs. The other 
two smaller subfamilies include the secretin-like receptors and the calcium- 
sensing/metabotropic glutamate receptors. Subfamilies are based on structural and 
genetic characteristics but share little intra-familial sequence homology. Unlike 
normal mammalian GPCRs, vGPCR signals on the absence of ligand. This 
constitutive activity is largely due to abnormal transmembrane helices two and 
three, as well as its cytoplasmic tail (121, 241). Additional mutational studies show 
that although the N terminus is required for ligand binding, it is not necessary for 
constitutive signaling (120, 229). Interestingly, despite its constitutive activity, 
vGPCR retains its ability to respond to various CXC and CC-type chemokines; 
these include agonists, inverse agonists, and antagonists. Agonists include IL-8 
and growth-related oncogene-a (GROa) (9, 98-100, 111, 229). Antagonists include 
neutrophil-activating peptide-2 (NAP-2) and epithelial cell-derived neutrophil- 
activating 78 (ENA-78) (229). Inverse agonists include interferon-y-inducible 
protein-10 (IP-10), stromal cell-derived factor-1 (SDF-1) and KSHV vCCL-ll, a viral 
CC chemokine (98, 99). Of note, it is the angiogenic ELR-positive (Glu-Leu-Arg 
prior to the first cysteine) CXC chemokines that are vGPCR agonists, while the non- 
ELR chemokines are inverse agonists (260). This has implications for vGPCR 
function and is discussed below. Another mechanism by which vGPCR may be 
modulated in vivo is via the GPCR-specific kinases (GRK), particularly the family 
containing GRK-4, -5, and -6 (97, 215). GPCRs in an active state can be bound by 
GRKs that lead to interaction with arrestin and inhibition of G protein interaction.
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The biologic importance of GRK-mediated downregulation of vGPCR remains to be 
studied.
KSHV vGPCR not only binds a huge array of ligands, but utilizes a surprising 
number of downstream effectors. These are cell-type specific so we will 
concentrate on the data in endothelial and hematopoietic cells since they are the 
natural targets for KSHV infection. vGPCR can signal via Gai and Gaq in both cell 
types (38, 62). Studies in HeLa cells suggest that coupling to Ga13 and RhoA may 
also be possible but this remains to be confirmed in a biologically relevant cell type 
(244). The Py subunits of both pertussis-sensitive (Gai) and pertussis-insensitive a- 
subunits also mediate vGPCR signaling (38, 62, 179, 250). The result is the 
activation of several kinases involved in endothelial and B cell proliferation. For 
example, vGPCR-mediated activation of a Gai-PI3K/Akt axis promotes endothelial 
cell survival; this is likely via activation of NFkB (62, 179, 208). Although NFkB is 
also activated in B cells, it is neither Gai- nor PI3K/Akt-dependent but rather 
mediated by a non-pertussis sensitive G protein such as Gaq (38). vGPCR also 
activates the mitogen- and stress-activated protein kinases (MAPK, SAPK) involved 
in cellular proliferation, angiogenesis, and inflammation via both Gaq and Gai G 
proteins (13, 37, 250). This results in additional transcription factor activation 
including AP-1, CREB, and hypoxia-inducible factor 1a (HIF1a); the latter has been 
shown to result in VEGF expression from COS-7 cells may well apply to endothelial 
and hematopoietic cells (252).
Nuclear factor of activated T cells (NFAT) is a transcription factor that acts in 
conjunction with AP-1 to enhance the expression of many proteins in the productive
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immune response; furthermore, it is required for the calcium-mediated latent-to-lytic 
switch in KSHV transcription pattern (164, 301). vGPCR induces NFAT activity via 
combined interaction with Gaq and Gai and that this is augmented by HIV-1 Tat 
(37, 209). Chiou et al. discovered that vGPCR upregulates transcription via the 
T 1.1/PAN, K1, and LLP latency promoters of KSHV, while others show a vGPCR- 
induced increase in the lytic products ORF 50 and ORF 57 in latently infected PEL 
cells (37, 58). So in addition to its effects on host cell transcription, it is clear that 
vGPCR has important effects on KSHV transcription patterns; as discussed later, 
this has important implications for the role of vGPCR in the KSHV viral life-cycle.
1.11.3 KSHV vGPCR and Disease Pathogenesis
KSHV vGPCR is a promiscuous receptor that activates cell survival signaling 
cascades, results in the elaboration of various cytokines, and can affect KSHV 
transcription patterns. Any or all of these functions may be vital to the pathogenesis 
of KSHV-mediated endothelial and B cell hyperproliferative syndromes. Some of 
the first vGPCR studies showed it transforms fibroblasts (9). However, arguing for a 
directly transforming role in KSHV-mediated disease is difficult: unlike the latent 
transforming viral genes of EBV, vGPCR is expressed in early lytic phase (135,
187). A lytically activated host cell is destined to die in the process of new virion 
production, so to express a viral oncogene under such circumstances appears at 
odds with promoting an autocrine survival advantage. Some have argued that early 
vGPCR expression in endothelial cells may set up a self-perpetuating growth- 
promoting paracrine loop via upregulation of VEGF and VEGF receptors (14); this is 
a very enticing scenario but requires further investigation.
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The bulk of evidence indicates that vGPCR has its most potent effects via a 
paracrine mechanism. KS and PEL tumors show that a relatively small subset of 
cells are KSHV-infected and even fewer express lytic genes such as vGPCR (72, 
160, 257, 268). Likewise, vGPCR-driven KS-like tumors in mice result from vGPCR 
expression by a subset of tumor cells (113, 291). All KSHV-driven tumors display 
some level of lytic replication. Given the instability of KSHV infection in most cell 
types, this is probably required to maintain ongoing infection and new virion 
production (147). When expressed from these lytically activated host cells, vGPCR 
could provide growth-promoting cytokine expression; and as a chemokine receptor 
involved in cell migration, it could also recruit new infectable cells to the tumor 
microenvironment. Figure 1.6 summarizes some of the cytokines and cell adhesion 
molecules upregulated by vGPCR that could explain its paracrine-driven 
proliferative effect on both hematopoietic and endothelial cells.
Despite its obvious potential to affect the tumor microenvironment, if vGPCR 
is expressed only briefly during the early lytic phase, the question remains as to 
how relevant its effects are in vivo. However, some evidence suggests vGPCR can 
be expressed in a dysregulated way, outside the normal KSHV lytic program (251). 
For example, HIV Tat can increase the expression of vGPCR; and the Ganem lab 
showed that vGPCR transcription is upregulated by RBP-Jk , a transcription factor 
and target of the Notch pathway (158, 292). If a sustained upregulation of vGPCR 
were to occur in an abnormal or abortive lytic phase, it becomes easier to reconcile 
its in vitro potential with tumorgenesis and effects on the viral life cycle.
Interestingly, abortive lytic cycle progression in which a subset of lytic genes is
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expressed has been shown in other herpesviruses. As discussed in Chapter 7, 
dysregulated vGPCR expression would have implications for our recent work. It 
opens up the possibility that dysregulated vGPCR expression leads to inhibition of 
full productive lytic replication. In this state of limbo between normal latent and lytic 
phases, vGPCR-mediated elaboration of angiogenic and mitogenic chemokines 
would have a more prolonged and biologically important effect.
Reconciling all the data on KSHV vGPCR into one well circumscribed 
function is not yet possible. In fact, current concepts in virology and tumorgenesis 
may require us to interpret vGPCR as having multiple seemingly discreet functions.
It is clear, however, that KSHV has devoted it evolutionary energies toward tight 
regulation of vGPCR: its expression is restricted in that it is transcribed within the 3’- 
end of a bicistronic message; furthermore, KSHV encodes its own inverse agonist 
of vGPCR, vCCL2. Such fine tuning of vGPCR signaling suggests that vGPCR may 
play different roles at different points in the KSHV life cycle. Work by Dezube et al. 
shows that during early de novo KSHV infection of endothelial cells, vGPCR 
transcription fluctuates in a cyclic pattern every 48-72 hours consistent with viral 
replication (70). So in addition to maintaining a suitable tumor microenvironment as 
discussed above, it may be that vGPCR has yet another role in early infection: 
perhaps to establish successful latency or encourage the initial rounds of KSHV 
replication.
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Figure 1.6. Sum m ary of signalling pathway, cytokines and adhesion  
molecules upregulated by KSHV vGPCR. KSHV vGPCR is known to activate 
the MAP kinases, Src-family members and PI3-kinase depending on the cell 
type studied. Various growth and angiogenesis related transcription factors are 
also activated as are adhesion molecules that might play a role in manipulating 
interactions between endothelial cells, haematopoietic cells and other cell types 
in KS lesions. Cytokine elaboration is also influenced by vGPCR and may be 
involved in cell recruitment and/or immune evasion strategies. Various cell 
types have been used to study vGPCR; shown above are endothelial (left) and 
haematopoietic cells (right).
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1.12 Other Pathogenic GPCRs
1.12.1 Introduction
Virus-encoded GPCRs have been described in several DNA viruses including 
Poxviruses and the p- and y-herpesvirus (Table 1.2). As exemplified by KSHV 
vGPCR, these viral GPCRs are more promiscuous in their use of ligands and 
downstream signaling cascades than their mammalian homologues. Such broad 
signaling has resulted in many postulated roles for viral GPCRs: immune evasion, 
viral entry and replication, cell migration, and even direct cell transformation. In 
addition to virally-encoded constitutive GPCRs, several mutated mammalian 
GPCRs are also responsible for human disease.
1.12.2 Human Herpesviral GPCRs
EBV is a ubiquitous lymphotropic y1-herpesvirus that infects and remains latent in 
over 90% of people by the time they reach middle age. Manifestations of acute 
infection often go unnoticed in children but can cause infectious mononucleosis in 
adolescents and adults. EBV infects the oropharyngeal epithelium and surface B 
cells of the tonsils; via the latter it disseminates throughout the reticuloendothelial 
system. Although infection persists throughout life, the immune-competent host 
generally suffers no long-term ill effects after the EBV-driven polyclonal B cell 
proliferation subsides; thanks in part to a vigorous cytotoxic T cell response. EBV 
can, however, contribute to more sinister sequelae: nasopharyngeal carcinoma is 
most prevalent in southeastern China; Burkitt’s lymphoma is one of the most
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common childhood malignancies in sub-Saharan Africa; post-transplant 
lymphoproliferative disorder is EBV-driven; and two-thirds of AIDS-related non- 
Hodgkin’s lymphomas are EBV-positive.
Very recently the EBV open reading frame BILF1 was demonstrated to 
encode afunctional, constitutively active GPCR that is heavily glycosylated and 
localizes to the plasma membrane in epithelial cell lines. The BILF1 signals via Gai, 
but not Gaq/11 as evidenced by its ability to inhibit forskolin-stimulated CREB 
activity in a pertussis-sensitive manner in COS-7 cells. Like KSHV vGPCR, BILF1 
appears to be an immediate-early product and can activate NFkB. Interestingly, 
BILF1 reduces levels of phosphorylated RNA-dependent anti-viral protein kinase 
(PKR). PKR is an interferon-inducible enzyme with a role in intracellular anti-viral 
defense; BILF1 is the first GPCR shown to potentially inhibit this pathway (18, 210, 
283). Further study of BILFTs role in the EBV life-cycle and its influence over host 
anti-viral responses are exciting prospects.
The p-herpesvirus family includes cytomegalovirus (CMV), human 
herpesvirus-6 and -7 (HHV-6, -7). In healthy hosts, acute CMV infection is a self­
limited flu-like syndrome and by adulthood, 70-90% of people are latently infected. 
Infection during pregnancy, however, can lead to serious birth defects including 
blindness, deafness, seizures, and microencephaly. In the setting of AIDS, CMV 
causes retinitis, gastrointestinal disease, and various neurologic syndromes. In 
solid organ transplants, CMV causes hematologic disorders, hepatitis, pneumonitis 
and organ rejection. In bone marrow transplants the more common complications 
are graft-versus host disease, delayed engraftment, and pneumonitis.
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The CMV genome encodes four GPCRs, two of which will be discussed 
here: US28 and UL33. Like KSHV vGPCR, HCMV US28 signals independently of 
an agonist but can be modified by CC chemokines and fractalkine (CX3CL1).
Unlike KSHV vGPCR, US28 is located predominantly endosomally, not on the cell 
surface (278). Expression of US28 results in migration of smooth muscle 
endothelial cells and it is therefore postulated to play a role in viral dissemination 
and CMV-driven vascular disease (41, 137, 258). A role in immune evasion is also 
argued by virtue of the high turn over of US28 and the resultant sequestration of 
host-produced chemokines (24). As discussed for KSHV vGPCR, another important 
role for US28 may lie in its latent expression in hematopoietic cells, resulting in 
homing to sites of inflammation rather than lymph nodes (259). HCMV UL33 also 
demonstrates constitutive basal activity but binds no known chemokines. It is 
incorporated into viral particles and expressed on virus infected cells (166). UL33 
activates CREB-mediated signaling and since many HCMV gene promoters contain 
CREs, it has been postulated that UL33 is involved in establishing viral infection or 
possibly reactivation (42). The rat and mouse CMV homologues of UL33 are 
important for replication in salivary glands and for general virulence, but similar 
studies are not available for HCMV UL33 (19).
Infection with HHV-6 and-7 generally occurs early in life. The former is the 
usual agent of exanthem subitum (also known as roseola infantum or sixth disease), 
a self-limited syndrome in children of fever and rash. Primary infection later in life 
causes an infectious mononucleosis syndrome much like EBV or CMV. HHV-7 is
59
Table 1.2 Human Herpesvirus G Protein-coupled Receptors
Virus Family Gene Constitutive References
HCMV P Us27
Us28
Ul33
Ul 78
HHV-6 P U12
U51
HHV-7 P U12
P U51
EBV yi BILF1
KSHV 72 ORF 74
Fraile-Ramos et al., 2002 
+ Kledal, et al., 1998
+ Marguiles et al., 1996
Bankier, DNA Seq., 1991 
2;1
Gompels et al., 1995 
Isegawa et al., 1998 
Milne et al., 2000
Nicholas et al., 1996 
Tadagaki et al., 2005 
Nicholas et al., 1996 
Tadagaki et al., 2005 
+ Beisser et al., 2005
Paulsen et al., 2005 
+ Bais et al., 1998
Rosenkilde et al., 1999
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not convincingly associated with disease in the normal host, but like HHV-6 may 
become reactivated in the immuncompromised patient (60). Two ligand-dependent 
GPCRs with homology to the CC-chemokine receptors are encoded by both HHV-6 
and HHV-7. U12 and U51 are positional and structural homologues of HCMV UL33 
and UL78 (103, 125, 175, 196). HHV-6 UL12 binds RANTES, macrophage 
inflammatory protein 1a and ip  (CCL3, CCL4), and MCP-1 (CCL2); HHV-7 UL12 
binds EBI1-ligand chemokine (ELC or CCL19), secondary monocyte 
chemoattractant lymphoid-tissue chemokine (SLC or CCL21), thymus and 
activation-regulated chemokine (TARC orCCL17), and macrophage-derived 
chemokine (MDC or CCL22) (188, 266). Both U12 homologues are functional and 
signal via non-Gai pathways resulting in transient calcium flux. HHV-7 U12 induces 
migration of stably transfected Jurkat cells toward ELC and SLC, but not TARC or 
MDC. This leads the authors to postulate that HHV-7 U12 induces the migration of 
infected cells towards lymph nodes, perhaps facilitating viral transmission (266). 
Little is known of the function of HHV-6 U12.
In both HHV-6 and HHV-7, UL51 is expressed in the immediate-early and 
early stages post-infection. Both homologues bind many CC-type chemokines as 
well as the KSHV-encoded homologue of vCCL2. HHV-6 UL51 downregulates 
transcription of RANTES which may lend it an immunomodulatory role but this 
requires further confirmation. Even less is known about the function of HHV-7 UL51 
(175).
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1.12.3 Non-Viral Constitutivelv Active GPCRs and Disease 
Aside from viral GPCRs, there exist several constitutively active GPCR mutants 
associated with human disease that may arise in germline or somatic cells (8, 61, 
254). Familial forms of hyperthyroidism and hypoparathyroidism are due to 
mutations in the thyroid-stimulating hormone receptor in the former, and the 
extracellular domain of the calcium-sensing receptor in the latter (52, 273). The 
retinal degeneration of retinitis pigmentosa is thought due to mutations in the 
seventh transmembrane domain of rhodopsin, leading to over activation of 
photoreceptor cells (225). Mutation of the rtiodopsin second transmembrane 
domain leads to congenital night blindness (220). A change in the sixth 
transmembrane helix of the luteinizing hormone receptor causes familial male 
precocious puberty as do other activating mutations (142, 243).
1.13 GPCR activation of protein tyrosine phosphatases
In Chapter 5 of this thesis I investigate the possible role of the non-receptor protein 
tyrosine phosphatases (PTPs) in conducting vGPCR-mediated signaling events. 
Important cell activities such as death, proliferation, and differentiation are regulated 
by signal transduction processes including protein phosphorylation and 
dephosphorylation; a balance of these is likely always in play. Although the protein 
tyrosine kinases (PTKs) are much better studied, the PTPs are likely as important 
and are increasingly the target of medicinal chemistry research (198, 216). 
Furthermore, very few studies on the interactions between GPCRs and PTPs have 
been performed. The PTPs will likely prove good candidates for rationally designed 
therapies and their role in GPCR signaling requires further investigation.
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It has recently been estimated that 81 human genes encode PTPs, which is 
very similar to the number for PTKs(4). The non-receptor PTPs contain include 
SHP-1 and SHP-2 which contain tandem SH2 domains; an SH2 domain is a 100 
amino acid motif that mediates binding to phosphorylated tyrosine residues on other 
proteins (141, 216). The SHP-1/2 SH2 domains are located near the N-terminus 
and are thought to bind intramolecularly to the PTP catalytic site thereby 
maintaining a basal inactive state. Once an appropriate phosphorylated tyrosine 
residue is encountered, however, an allosteric shift occurs activating the catalytic 
domain (for review, see (214)). SHP-2 is ubiquitously expressed, while SHP-1 is 
primarily found in haematopoietic cells (1, 293). SHP-2 has been implicated in 
many signaling pathways initiated by growth factors, including PDGF, EGF, IL-3, 
EPO, and GMCSF (122, 192). In some cases, SHP-2 appears to bind directly to 
certain receptors, but it also binds to many signaling intermediates such as p85, 
Grb2, Gab1, and Gab2. Despite its dephosphorylating activity, catalytically inactive 
dominant negative mutants of SHP-2 show that SHP-2 often functions in a positive 
way to enhance signaling; although it does negatively regulate JAK-STAT and p130 
signaling (265, 295). It is also possible that in some cases, SHP-2 functions as a 
scaffolding protein and its phosphatase activity is not required to conduct a signal 
(163). Mouse studies have shown a role for SHP-2 in lymphoid, erythroid, and 
myeloid lineage differentiation (217, 218). SHP-1 on the other hand seems to 
negatively regulate haematopoietic cell growth and homozygous mutants develop 
systemic autoimmune disease associated with high levels of autoantibodies and 
excessive erythropoiesis (247, 248). Generally speaking SHP-1 has opposing
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effects to SHP-2: SHP-1 attenuates signals from EPO, IL-3, and GM-CSF receptors 
and mediates inhibitory signals from y Fc domains, TCR, BCR, and the NK 
inhibitory receptor (35, 55, 64, 294).
The most important phosphotyrosyl-containing motif that activates SHP-1 
and SHP-2 is the immunoreceptor tyrosine-based inhibitory motif (ITIM). Once 
phosphorylated, variants of this consensus motif (l/V/L/S-x-Y-x-x-LVV) bind the N- 
terminal SH2 domain and activate the phosphatase catalytic site. The ITIM motif is 
also necessary to the inhibition, mentioned above, of B cell activation by the Fey 
receptor and the killer inhibitor receptor (KIR) of NK cells(63, 202).
We have noted that the KSHV vGPCR contains an ITIM consensus motif 
(LIYSCL) at the junction of the seventh transmembrane domain and the carboxy tail 
(see Figure 1.7). Interestingly, Duchene et al. have found that the bradykinin B2 
receptor interacts directly with SHP-2 via an ITIM motif in the same location (71). 
Activation of the receptor resulted in increased SHP-2 phosphatase activity and 
which was necessary to the anti-mitogenic effects of bradykinin. There are, 
however, reports of GPCRs that activate SH2-containing PTPs in the absence of an 
ITIM. Furthermore, the angiotensin II receptor AT2 bears an ITIM but it is 
dispensable for SHP-1 activation (81, 157, 224, 255). Whether KSHV vGPCR 
activates the SH2-containing PTPs and if its ITIM motif is involved is addressed in 
this thesis.
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Figure 1.7. Schematic of KSHV vGPCR from GPCRDB data base. Shown is a 
schematic of KSHV vGPCR using single letter amino acid code. Note the seven 
transmembrane bundles. The amino terminus extends extracellulariy while the 
carboxy terminus sits intracellularly. An ITIM consensus site LIYSCL is located at 
the junction of transmembrane domain 7 and carboxy tail, (httpy/www.qpcr.org/7tmA.
1.14 The role of TGFp in Cancer
Chapter 6 of this thesis is a short chapter in which I present work I have done as 
part of a collaboration with Dr. Ethel Cesarman at Cornell Medical College in New 
York. We simultaneously discovered defects in the TGFp pathway in PEL cells and 
are further exploring this.
TGFp exists as three isoforms: TGFpl is universally expressed and the most 
abundant. It is secreted as a latent protein complex; after activation it binds to type I 
(TpRI) and type II (TpRII) receptors that are also ubiquitously expressed and have 
high affinity for TGFp (for review, see (12)). The receptors contain cytoplasmic 
domains that are serine/threonine kinases. After binding ligand, TpRII recruits TpRI 
which in turn recruits and phosphorylates the transcription factors SMAD2/3. These 
in turn bind SMAD4 and translocate to the nucleus to interact with various 
transcription factors, coactivators and corepressors thereby regulating transcription 
of TGFp-responsive genes (171, 189, 287).
TGFp regulates both haematopoiesis and immune function; perturbation of 
both these processes is critical to the development of several haematologic 
malignancies and may be the case for KSHV-driven PEL and MCD. Effects on 
haematopoietic cells are cell type and context specific. For example, in progenitor 
cells, TGFp signaling is an anti-proliferative and differentiating force. This 
maintenance of quiescence in early haematopoietic progenitors is less potent on 
later progenitors (87, 230). Via its effects on antigen presenting cells (APCs) and T 
cells, TGFp has a predominantly immunosupressor role. It can block both the
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1.14 The role of TGFp in Cancer
Chapter 6 of this thesis is a short chapter in which I present work I have done as 
part of a collaboration with Dr. Ethel Cesarman at Cornell Medical College in New 
York. We simultaneously discovered defects in the TGFp pathway in PEL cells and 
are further exploring this.
TGFp exists as three isoforms: TGFpl is universally expressed and the most 
abundant. It is secreted as a latent protein complex; after activation it binds to type I 
(TpRI) and type II (TpRII) receptors that are also ubiquitously expressed and have 
high affinity for TGFp (for review, see (12)). The receptors contain cytoplasmic 
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transcription factors, coactivators and corepressors thereby regulating transcription 
of TGFp-responsive genes (171, 189, 287).
TGFp regulates both haematopoiesis and immune function; perturbation of 
both these processes is critical to the development of several haematologic 
malignancies and may be the case for KSHV-driven PEL and MCD. Effects on 
haematopoietic cells are cell type and context specific. For example, in progenitor 
cells, TGFp signaling is an anti-proliferative and differentiating force. This 
maintenance of quiescence in early haematopoietic progenitors is less potent on 
later progenitors (87, 230). Via its effects on antigen presenting cells (APCs) and T 
cells, TGFp has a predominantly immunosupressor role. It can block both the
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proliferation and maturation of T cells; autocrine TGFp inhibits macrophage 
activation and promotes dendritic cell differentiation (25, 104, 132, 223).
Resistance to the homeostatic functions of TGFp is common among 
haematologic malignancies. The most common mechanisms include 
downregulation of the TGFp receptors or interference of signaling intermediates by 
oncoproteins such as Evi-1 and HTLV-1 Tax (146, 182). Solid tumours, on the 
other hand, more commonly acquire mutations of the receptors or SMADs (146). In 
this thesis we will see that PEL cells down-regulate TpRII and that exogenous 
expression of this molecule reconstitutes transcriptional and phenotypic 
responsiveness of PEL cells to TGFp. Possible roles for KSHV-mediated 
downregulation of the TGFp pathway will also be discussed.
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CHAPTER 2: MATERIALS and METHODS
Standard techniques 
2.1 Cell Culture
The PEL cell lines used were maintained in RPMI 1640 plus 40 mg/L gentamicin 
(Invitrogen) with 10% FBS (Atlanta Biologicals, Norcross, GA) at 37QC, 5% C02. 
HEK293, 293T, and NIH3T3 cells were maintained in DMEM plus 40 mg/L 
gentamicin (Invitrogen) with 10% FBS.
2.2 Agarose gel electrophoresis
Plasmids and DNA fragments were resolved on agarose gels to assess digestion 
and fragment sizes. Agarose concentration varied from 1-2% in 1x TAE. Ethidium 
bromide (Sigma) was added to agarose to stain DNA and a 1kB DNA size ladder 
(Invitrogen) was used to determine DNA sizes. Bands were visualized using a UV 
transilluminator.
2.3 D N A  ex trac tio n
For gel purification, DNA bands were excised with a clean scalpel and purified using 
the QIAquick (Qiagen) extraction kit as per manufacturer’s protocol. 30j.il of water 
was used to elute DNA from the column. The same kit was used to clean up DNA 
produced by PCR reaction.
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2.4 DNA ligation
DNA fragments were ligated in a volume of 20 \i\ at a molar ratio of 3:1, 
plasmid:insert. Ligation was performed at room temperature for 1 hour using DNA 
ligase (New England Biolabs).
2.5 Construction of tetracycline-responsive vGPCR-expressing plasmid
pTRUF2-Tet was constructed by initially cloning all the tetracycline regulatory 
elements into the cloning vector pSL301 (Invitrogen). The entire cassette was then 
transferred from pSL-301 to pTRUF2 (gift of Nicola Philpott, ICH, UCL)(302). In 
brief, pTet-tTS (Clontech) was digested with Xho\ and H/'ndlll and the resulting 
2,098-bp tTS insert was blunted and ligated into the EcoRV site of pSL-301 to make 
pSL301-tTS. Next, pTet-On (Clontech) was digested with Xho\ and PvuW and the 
resulting 2,398-bp rtTA fragment was blunted and ligated into the Sma\ site of 
pSL301-tTS to make pSL301-tTS-rtTA. Next, a simian virus 40(SV40) pA tail was 
excised from pTRE (Clontech) by digestion with BamHI and PvuW, the fragment was 
blunted and ligated into the Sfulsite of pSL301-tTS-rtTA to create pSL301-tTS-rtTA- 
pA. Next, the tetracycline-responsive promoter was excised from pTRE by digestion 
with Xho\ and EcoRI, blunted, and ligated into the/Vrul site of pSL301-tTS-rtTA-pA 
to create pSL301-tTS-rtTA-pA-TRE, which was then digested with PfM\ and AflW to 
remove the entire tetracycline-responsive cassette; the 5,886-bp fragment was 
blunted and ligated into the MfeI site of pTRUF2 to create pTRUF2-Tet(12,168 bp). 
pTRUF2-Tet-vGPCR was made by digesting pcDNA3.1-SacA, a plasmid derived 
from a genomic clone, with Xba\ and EcoRlto excise the vGPCR ORF (48). The
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vGPCR fragment was blunted and ligated into the blunted single A/s/1 site in 
pTRUF2-Tet. Restriction enzymes were from Roche; T4 polymerase and the 
Klenow fragment used for blunting were from Fermentas.
2.6 Derivation of ceil line BC3.6 and BC3.14
BC-3, an Epstein-Barr virus (EBV)-negative, KSHV-positive PEL line, was 
maintained in RPM11640 plus 40 mg of gentamicin (Invitrogen) per ml with 10% 
fetal bovine serum (Atlanta Biologicals, Norcross, Ga.) at 37°C under 5% C 0 2 (10). 
BC-3.6 and BC-3.14 were established by electroporation of BC-3 with 10 pg of 
pTRUF2-Tet-vGPCR. The cells were allowed to recover for 48 h in full culture 
medium, and then 1 mg of G418 (Invitrogen) per ml was added. After 2 weeks under 
antibiotic selection, single cells were placed on irradiated fibroblast feeder layers (1 
x 104 to 2 x 104 cells/well; 5,000 rads of cobalt '-irradiation) in 96-well plates by 
limiting dilution. After 2 weeks, wells with a single green fluorescent protein-positive 
colony were expanded and those with two or more were discarded. After reaching 
sufficient numbers, 48 lines were each screened for intact tetracycline inducibility- 
related protein expression by transfection, as described below, with 10 pg of pTRE- 
Luc (Clontech). Transfectants were split into two samples, one of which received 2 
pg of doxycycline (Sigma) per ml. At 48 h, lysates were prepared and luciferase 
assays were performed. Lines with low background and high luciferase induction 
were used for vGPCR binding assays to assess the inducibility of vGPCR 
expression.
70
2.7 Transformation of competent bacteria
For most experiments competent e.coli used were TOP10 (Invitrogen). Bacteria 
were thawed on ice, DNA added and let mix with bacteria for 30 minutes, after 
which bacteria were heat shocked for 45 seconds at 429C. Fresh medium was 
added and bacteria allowed to recover for 60 minutes at 37QC before plating onto 
agar plates supplemented with 100 pg/ml ampicillin.
2.8 Plasmid extraction and purification
For small scale extraction and purification of Plasmid DNA, alkaline lysis followed by 
affinity column capture was performed with the MiniPrep Kit (Promega) as per 
manufacturer's protocol. For larger scale production, alkaline lysis was followed by 
addition of isopropyl alcohol, centrifugation and resuspension in TE. Sample was 
then extracted with phenol:chloroform:isopropyl alcohol in a 1:1 ratio. After a 5 
minute spin at 12000 rpm, the aqueous phase was removed and sodium acetate 
added to a final concentration of 0.3 M. 2.5 volumes of 100% ethanol were added to 
precipitate the DNA which was then pelleted, washed in 75% ethanol and then 
resuspended in TE.
2.9 Polymerase chain reaction
PCR was used to amplify DNA for cloning of ORFs, including the addition of epitope 
tags where required. It was also used in semi-quantitative RT-PCR experiments. 
PCR was performed in a 96-Plus thermocycler (MWG Biotech, UK). Expand High-
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Fidelity DNA polymerase (Roche) was used when proof-reading was required. 
Otherwise, standard Taq polymerase (Roche) was used. Typical reaction mixture 
included 0.2 pm of sense and anti-sense primers (see Table 2.2), 5 pi of 10x buffer 
(containing MgCI2), 200 pM dNTP, 0.5 units of polymerase, and DNA template in 
total volume of 50 pi. Parameters generally included 30-35 cycles at 959C for 1 
minute, 559C, for 1 minute, and 729C for 3 minutes followed by final cycle of 729C 
for 10 minutes. For real-time PCR see 2.2.
2.10 Mutagenesis
To create vGPCR mutants Y314F and ALY, the QuikChange II Site-Directed 
mutagenesis Kit (Stratagene) was used. pKSHV-vGPCR was amplified using 
primers containing the desired mutations (see Table 2.2) for 12 cycles with an 
annealing temperature of 55eC (1 minute) and an elongation temperature of 689C (6 
minutes). After amplification, the product was digested for one hour at 379C to 
destroy the input pKSHV-vGPCR plasmid. One Shot Top Ten chemically competent 
E. coli were then transformed, colonies picked and grown the next day, followed by 
plasmid mini-preparation and sequencing by the Wolfson Institute Scientific Support 
Services Group.
2.11 Restriction digest analysis
Plasmids and/or DNA fragments were digested when necessary for cloning in a 10 
pi reaction mixture consisting of 200 ng DNA, 1 ml of 10x buffer, and 0.5-1 units of
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restriction enzyme. Reactions were incubated at 37SC for an hour. All restriction 
enzymes were from Promega.
2.12 RNA extraction
Approximately 2-5 x 106 cells were homogenized in o.5 ml of TRI Reagent. RNA 
was extracted by adding 0.1 ml chloroform and mixing vigorously, followed by 
centrifugation at 12000 rpm for 15 minutes at 4QC. To the aqueous phase was 
added 0.25 ml isopropanol, followed again by centrifugation as above. The pellet 
was washed in 75% ethanol, air dried for 10 minutes and then solubilised in 30 |al of 
water. Prior to use for reverse transcription, a 1 ^g aliquot of RNA was treated for 1 
hour at 37QC with DNase 1 (Roche), followed by heat inactivation of the DNase 1 at 
75eC for 10 minutes in presence of 5 mM EDTA.
Cellular staining and analysis 
2.13 Annexin V and PI staining
Cells were washed twice with ice-cold PBS and then suspended in 1x binding buffer 
(0.1 M HEPES pH 7.4, 1.4 M NaCI, 25 mM CaCI2) at a concentration of 
approximately 1 x 106. 100f.il of suspension was transferred to a 5 ml culture tube to 
which 5 fil of annexin V-FITC (BD Pharmingen, cat# 556420) and 2 pi of PI (stock 
concentration 50 pg/ml) were added. After incubation for 15 minutes at room 
temperature in the dark, 400 pi of binding buffer was added and cells were analyzed
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by flow cytometry. As controls for compensation adjustment, unstained cells and 
cells singly stained for PI or annexin V were also analyzed.
2.14 Immunofluorescence
HEK 293 cells were grown overnight on glass coverslips in 6-well plates. They were 
then transfected with plasmid constructs as shown in Figures. 48 hours post­
transfection, cells were washed three times in cold PBS and blocked for one hour 
with 1% BSA in PBS. Cells were then incubated with anti-FLAG antibody (M2 
clone, Sigma) at a dilution of 1:500 in PBS with 1 % BSA for 1 hour in a humid 
chamber. Cells were then gently washed three more times in cold PBS followed by 
one hour incubation with a 1:60 dilution of anti-mouse-FITC antibody in PBS with 
1% BSA. After three more washed in PBS, coverslips were inverted onto glass 
slides containing one drop of Vectashield with DAPI (Vector Laboratories, 
Burlingame, CA). Images were obtained using an Axiovert 100 microscope, LD 
Acroplan 20x/0.04 numeric aperture objective, Axiocam camera, and Axiovision
3.0.6 software (all from Zeiss, Oberkochen, Germany).
2.15 Flow Cytometry
Forty-eight hours after transfection, HEK 293 cells were detached with a dilute 
Trypsin solution and washed in cold PBS. They were then resuspended in 50 pi of 
a 1:40 dilution of anti-FLAG antibody (M2 clone, Sigma) in PBS with 1% BSA and 
allowed to stand on ice for one hour. Cells were washed once in cold PBS and then 
stained with anti-mouse-FITC secondary antibody at a dilution of 1:60 in PBS, 1%
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BSA for one hour. Cells were washed twice in cold PBS and resuspended in a 
volume of 100 pi of PBS. Ten thousand cells were then analyzed using a 
Facscalibur flow cytometer (Becton-Dickinson, Franklin Lakes, NJ)
2.16 Cell Cycle Analysis
BC3.14 cells in exponential growth were incubated for 48 hours with or without 
doxycycline and then fixed with 70% ethanol overnight. Forty eight hours was 
chosen as the time point based on our previous work with BC3.14 showing that 
vGPCR signaling and phenotypic effects are not seen prior to 48 hours. They were 
then stained with propidium iodide at a final concentration of 50 pg/ml with RNaseA 
100U/ml. When nocodazole (Sigma, St. Louis, MO) was used to inhibit mitosis, it 
was added for 17 hours to cells at a final concentration of 0.2 pg/ml. Ten thousand 
cells were then analyzed using CellQuest and ModFit on a Facscalibur flow 
cytometer (Becton-Dickinson, Franklin Lakes, NJ). To quantify S-phase, cells were 
incubated in the dark at 37QC for 4 hours in the presence of 100 pM BrdU (Sigma). 
They were then plated using a Cytospin 2 (Shandon, Thermo Electron Corporation, 
Waltham, MA) and fixed for 30 minutes with 70% ethanol. Cells were washed in 
PBS and incubated for 15 minutes with 2N HCI to denature genomic DNA. After 
several more PBS washes, 70 pi of staining solution was added (50 pi PBS with 
0.5% BSA and 0.5% Tween-20, 20 pi anti-BrdU-FITC (BD Pharmingen, Franklin 
Lakes, NJ)) and cells were incubated for 1 hour in a dark humid chamber. Cells 
were then washed and mounting medium with DAPI was applied (Vector 
Laboratories, Burlingame, CA). At least 100 cells were counted and S-phase
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expressed as the percentage of FITC-staining cells relative to total number of DAPI- 
staining cells. Images were obtained using an Axiovert 100 microscope, LD 
Acroplan 20x/0.04 numeric aperture objective, Axiocam camera, and Axiovision
3.0.6 software (all from Zeiss, Oberkochen, Germany).
Transfections and Luciferase assays 
2.17 Transfections
Transfections of BC3.14 were performed on exponentially growing cells by 
electroporation (Bio-Rad Gene Pulser II, Bio-Rad, Hercules, CA) at settings of 270 
mV and 975 mF in 0.8 cm cuvettes (Invitrogen, Carlsbad, CA), using 8x106 
cells/cuvette resuspended in 0.8 ml RPMI 1640. Cuvettes were prechilled on ice, 
and after transfection, cells were quickly plated in full culture medium as described 
above. HEK293, 293T, and NIH3T3 cells were transfected in 6 cm dishes or 6-well 
plates (-40% confluent) using Fugene 6 per manufacturer's protocol (Roche 
Diagnostics).
2.18 Luciferase Assays
For BC3.14 luciferase assays, 10 ^g of the reporter-luciferase construct were 
transfected and cells were then divided evenly and plated with or without 
doxycycline (Calbiochem, EMD Biosciences, Darmstadt, Germany). After 48 h, 
lysates were prepared using 1x Cell Culture Lysis Reagent as per the 
manufacturer’s directions (Promega, Madison, Wl). Assays were performed using
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10 pi of lysate and 50 pi of beetle luciferin in a Fluoroskan Ascent FL (Thermo 
Electron), using a 10-s read time. Protein concentration was used for normalization 
and was determined by the Bradford method with Bio-Rad DC Protein Assay 
Reagent after diluting samples and standards 1:1 in PBS. Since cells were divided 
after transfection, transfection efficiency was inherently controlled for, and protein 
equalization was deemed sufficient.
Luciferase assays in HEK293 cells were performed 48 hours after transfection of 
300 ng of Luciferase reporter construct (along with other constructs as indicated in 
figure legends). 15 ng of TK-renilla was included to control for transfection 
efficiency. Lysates were made at 48 hours using the Passive Lysis buffer included 
in the Dual Luciferase Kit (Promega). Assay was performed as described above 
with the addition of a 10-s read time for renilla values. All firefly values were 
normalized to renilla values to control for transfection and harvesting efficiency.
Protein Biochemistry
2.19 immunoprecipitation and phosphatase assay
For immunoprecipitation experiments, FIEK 293 cells were lysed in RIPA buffer 48 
hours after transfection. 800-1000 mg of lysates was incubated overnight with 2 pg 
of the appropriate primary antibody followed by one hour incubation with Protein G- 
plus beads (Santa Cruz). The immunocomplex was washed three times in RIPA 
buffer and the pellet resuspended in 2x loading buffer. The complex was boiled for
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2-3 minutes and loaded on 10% PAGE gels. Immunoblotting was performed as 
below.
In the case of immunoprecipated phosphatase assays, cells were lysed in CHAPS 
lysis buffer (50 mM Tris-HCL pH 7.5, 1.5% CHAPS, 150 mM NaCI, 5 mM EDTA, 
protease inhibitors). Prior to IP, 4 ^g of anti-SHP2 antibody was incubated for 1 
hour with 50 fil packed protein G-plus beads (Santa Cruz) in lysis buffer then 
washed to remove unbound antibody. 800 mg was then added to the antibody- 
bead complex and rotated at 49C for 2 hours. IP complexes were then washed 
twice in lysis buffer, twice in wash buffer (same as lysis buffer minus CHAPS), then 
twice in PTPase buffer (50 mM Tris-HCL pH 7.0, 1 mg/ml BSA. 5 mM DTT. IP 
complexes were then resuspended in 50 jal PTPase buffer with 0.2 mM 
phosphorylated peptide RRLIEDAEpYAARG (Raytide, Upstate) and incubated for 
30 minutes at 30QC in a shaker. IP complexes were then pelleted and 25 jal of 
supernatant was assayed for a molybdate :malachite green:phosphate reaction 
complex by adding 100 jal of malachite green solution (Upstate), incubating for 15 
minutes, then reading absorbance at 620 nm. Values were compared to a standard 
curve to derive free phosphate concentration.
2.20 Western blotting
BC3.14 cells were plated in full growth medium at 4x105/ml in a 24-well plate and 
subjected to 2^g/ml doxycycline for various time periods as indicated in figure 
legends. Cells were diluted to keep below 1.0 x 106/ml to minimize effects of 
crowding. Cells were lysed with standard RIPA buffer with 1 mg/ml each of
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aprotinin, leupeptin, and pepstatin, 0.5mM PMSF, and 1mM each of NaV04 and 
NaF (Sigma). Protein was quantitated by the Bradford method and loaded onto 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using 10- 
12% gels. Semidry transfer to PVDF (Millipore, Billerica, MA) was performed using 
transfer buffer, 48mm Tris, 39mm glycine, 0.037% SDS, and 20% methanol. Blots 
were probed with primary antibody (Ab) overnight at 41QC. HRP-conjugated 
secondary Ab was added after washing and detected by an enhanced 
chemiluminescence system (ECL) (Amersham, Little Chalfont, UK).
Western blotting in the case of HEK293, 293T, and NIH3T3 cells was similar in that 
after transfection, cells were incubated for 24-48 hours and lysed in RIPA buffer as 
above. Protein separation, transfer and blotting procedures were the same as for 
BC3.14 cells.
2.21 Kinase Assays
BC3.14 cells were lysed in IP buffer (50 mM HEPES pH 7.5, 150 mM NaCI, 1 mM 
EDTA, 2.5 mM EGTA, 10% glycerol, 1mM DTT, 0.1% Tween-20, 10 mM p- 
glycerophosphate, 1 mM NaF, 0.1 mM sodium orthovanadate, 2 pg/ml aprotinin, 5 
pg/ml leupeptin, 0.1 mM PMSF); 800pg of protein was precleared and then 
incubated overnight at 49C with 2 pi of the appropriate anti-Cdk antibody and 20 pi 
of protein G plus-agarose beads (Upstate). Beads were then washed four times in 
IP buffer and twice in 50 mM HEPES with 1 mM DTT. Kinase reactions were carried 
out in 30 pi of kinase buffer (50 mM HEPES, 10 mM MgCI2, 1 mM DTT, 10 mM p-
79
glycerophosphate) along with 10 pg substrate, GST-RbC-pocket (aa 773-928).
Cold ATP to final concentration of 50 pM with 10 pCi of y-^P ATP (6000 Ci/mmol) 
was added and mixture incubated at 30QC for 30 minutes. The reaction was 
stopped by addition of Laemmli buffer and brief boiling. The reaction product was 
loaded and run on a 10% SDS-PAGE gel, dried and exposed overnight. Blots were 
also incubated with anti-Cdk2 antibody to check for equal loading. Antibodies used 
included: anti-Cdk2(M2), anti-Cdk4(C22), anti-Cdk6(C21) (Santa Cruz).
For the in vitro Src kinase assay, cells were lysed with modified RIPA buffer (50 mM 
Tris (pH 7.5), 500 mM NaCI, 10 mM MgCI2 1% Triton, 0.1% SDS, 0.5% DOC, 1 pM 
EDTA and protease inhibitors as above). 800 pg of lysate was incubated overnight 
at 4°C with 2 pg anti-Src antibody and 30 pi Protein G-Plus agarose beads (Santa 
Cruz). Beads were washed three times in lysis buffer and twice in kinase buffer (20 
mM Tris (pH 7.5), 5 mM MgCI2 0.1% NP-40, 0.1 mM NaV04). Kinase reaction was 
performed for 15 minutes at 30°C in 30 pi kinase buffer with 5 pM cold ATP, 3 pCi 
[y-32P]ATP (3000 Ci/mmol; Amhersham). Reaction was stopped with loading buffer 
and boiled for 5 minutes, 35 pi of sample was run on 10% PAGE gel after which gel 
was fixed, dried and exposed to detect auto-phosphorylated Src. 4 pi of same 
product was used for Western using the same anti-Src antibody to control for total 
protein loaded.
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2.22 Binding assay
BC-3 and its derivative cell lines, while growing in exponential phase, were 
subjected to various doses of doxycycline for 48 h. Aliquots (2 x 106 cells) were then 
washed in cold phosphate-buffered saline and resuspended in 200 pi of binding 
buffer (RPM11640 with 10 mg of bovine serum albumin (Sigma) per ml and 25 mM 
HEPES). Samples were incubated in duplicate for 2 h with 0.1 ng of 125l-GROa 
(2,200 Ci/mMol) (Amersham) in a total of 400 pi of binding buffer, after which they 
were centrifuged through a 0.75-ml sucrose cushion (20% sucrose, 140 mM NaCI, 
40 mM Tris [pH 7.6], 0.4% BSA) at 3,000 rpm (500 x g) for 5min. Approximately 0.8 
ml of supernatant was discarded, and the tubes were centrifuged again. The 
remainder of the supernatant was carefully removed, the tips of the tubes were cut 
off, and the contents were counted for radioactivity in a ‘ counter.
Real-Time quantitative polymerase chain reaction 
2.23 Quantitative RT-PCR (qRT-PCR)
Total RNA from cells was treated with DNase I (RNase-Free, Ambion, Oxon, U.K.) 
before cDNA synthesis according to the manufacturer's instructions. cDNA was 
generated from 1 pg of total RNA by using the Superscript III First-Strand Synthesis 
System for RT-PCR (Invitrogen). Real-time qRT-PCR was performed on an ABI 
PRISM 7700 sequence detector (Applied Biosystems) by using the SYBR Green 
PCR Master Mix (Applied Biosystems, Foster City, CA) in duplicate, with triplicate 
nontemplate controls (NTCs) in a 25-pl PCR reaction. One microliterof cDNA was
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used in a 25-pl PCR mixture containing IxSYBR Green PCR Master Mix and 0.3 
MM GAPDH primers (5'-GGA GTC AAC GGA TTT GGT CGT A and 3'-GGC AAC 
AAT ATC CAC TTT ACC AGA GT), or 0.5 jiM of primers as shown in table 2.2.
The Q-PCR technique is based on detecting the amplified PCR product by labeling 
with a fluorescent dye. The SYBR Green dye stains double-stranded DNA formed 
by the polymerase. To normalize SYBR Green signal between wells, an internal 
reference dye is incorporated into the PCR AMpliTaqGold buffer; its signal is 
independent of the PCR reaction. Normalized reporter signals (Rn) from reactions 
containing cDNA template (Rn+) and non-template (Rn-) controls are calculated 
before there is detectable SYBR Green fluorescence. The normalized reporter 
signals from the template and non-template controls are used to calculate ARn (Rn+ 
minus Rn-). ARn is then plotted on an amplification plot against cycle number to 
analyze amplification of target sequence. Increases of ARn above the initial 
baseline indicate generation of PCR product. To determine the threshold cycle (Ct), 
the cycle at which amplification of product becomes statistically significant, a 
threshold is calculated as the average standard deviation of ARn in the early 
reaction, multiplied by an adjustment factor. Ideally, the threshold should lie in the 
linear range of the plot. From the threshold, Ct is then determined.
Q-PCR is also simultaneously performed for the housekeeping gene GAPDH to 
normalize between samples. The Ct for GAPDH is calculated in the same manner 
as above. The difference between the target product Ct and the GAPDH Ct is called 
ACt. The ACt value for each sample is the then compared to one reference sample
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to give AACt. The final value for the relative expression of a transcript is expressed 
as a negative power of2 (2 AACt).
Unwanted primer dimerization can be detected when optimizing Q-PCR primers 
using a dissociation curve program. This denatures the cDNA and then heats the 
reaction from 609C to 959C over 20 minutes to induce annealing and thereby 
generates a fluorescent signal when 50% of the primers dissociate. The presence of 
more than one signal at different temperatures suggests formation of primer dimers.
2.24 Primer design for Q-PCR
Primers were designed using Primer Express® (PE Applied Biosystems, UK) based 
on default parameters and guidelines.
Lentivirus production and transduction 
2.25 Lentivirus production
The lentiviral vectors used in this project are based on human immunodeficiency 
virus-1 (HIV-1) and were generated from the pHR’SIN parental construct (67).
There is no HIV viral protein expression from this plasmid. The vectors are self- 
inactivating due to a deletion in the 3’ HIV-1 LTR (303), so that only the internal 
promoter will be active in transduced cells. Broad tropism is obtained by generating 
vectors with the G glycoprotein of vesicular stomatitis virus (VSV-G) envelope (34). 
Confluent HEK 293T cells were split 1:5 into 10 cm dishes the day prior to 
transfection. Using Fugene 6, cells were transfected with 1 pg of plasmid p8.91
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(expressing gag-pol), 1 pg pMDG (VSV-G expressing plasmid) and 1.5 pg of pHR- 
Sin-CSGW-ANot1 which expresses GFP. To insert an alternative expression 
cassette, the plasmid was digested with Bam H1 and Not 1 to release the GFP 
insert and the transgene of choice was ligated into the Bam H1-Not 1 site. The cell 
culture medium was changed the next day. Cell medium was collected 72 hours 
post-transfection and spun for 2 hours at 28000 rpm . The pellet was resuspended 
in serum-free medium. Virus was tittered by infecting 100,000 293T cells with 10 pi 
of concentrated virus. After 72 hours, cellular DNA was isolated and Q-PCR 
performed for both lentiviral DNA and GAPDH. A titer of copies of lentivirus per cell 
was then calculated.
2.26 Cell transduction with lentivirus
1-5 x 105 BC3.14 cells were resuspended in fresh medium to which was added 1 ml 
of lentivirus at an MOI of 5 genomes per cell. Both cells and virus were first 
incubated for 15 minutes with polybrene to neutralize surface charge and to 
enhance virus-cell binding. Cells were harvested for protein or cDNA 48-72 hours 
after infection.
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Solutions for Standard Methods
1xTE
TAE (50x)
DNA loading buffer
Protease Inhibitors
Laemmli Sample Buffer 
(4x)
10mM Tris pH 7.5 
1mM EDTA
242g Tris base 
57.1ml acetic acid 
100ml 0,5M EDTA
60% (w/v) sucrose solution 
0.1% (w/v) bromophenol blue
0.1mM NaF 
0.1 mM Na3 V 04 
2 mg/ml aprotonin 
100 mg/ml PMSF
250 mM Tris pH 6.8 
0.02% (w/v) BPB 
4% (w/v) 2-pME 
8% (w/v) SDS 
40% (v/v) glycerol
Solutions for Protein Biochemistry
RIPA lysis buffer 50mM Tris pH 8.0
150 mM NaCI 
1 % NP-40 
0.1% SDS
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Kinase assay buffer(10x) 500 mM HEPES pH 7.4
100 mM Mg Cl2 
10 mM DTT
ATP stock (100 mM) 60 mg ATP
Adjust to ph 7.0 with NaOH 
Distilled water to 1 ml
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Table 2.1 Cell lines used in this thesis
Cell line ATCC # Morphology Organsim Growth Reference
HEK 293 CRL-
1573
Epithelial Homo
sapiens
adherent Graham FL et al, 
J Gen Virol 
1977 36(1) p59
BC3 CRL-
2277
Lymphoblast Homo
sapiens
suspension Arvanitakis L 
etal, Blood 1996 
(88)p2648
NIH-3T3 CRL-
1658
Fibroblast Mus
musculus
adherent Jainchill JL et al, 
J Virol 1969 4(5) 
P549
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Table 2.2 Primer sequences used in this thesis
Primer Use Sense/
Anti­
sense
Sequence
ITIM_Mut5’ S CGTGGTTCCCCTGATATTCTCCTGCCTGGGATCCC
ITIM_Mut3’ mutation A GGG AT CCCAGGC AGGAGAAT AT CAGGGG AACCACG
ALY_Mut5’ S GCGTCAGTCTAGCGCTGTACCTCCTGGTGGCATATTCT
ACGC
ALY_Mut3’ A GCGT AGAATATGCCACCAGG AGGT ACAGCGCT AG ACT 
GACGC
NheFLAG s GT GCT AGCCACC ATGGACT AC AAGG ACGACGAT GACAAGG
VGCR5’ epitope CGGCCGAGGATTTCC
XhovGCR3’ insertion A TTCT CGAGCTACGT GGT GGCGCCGGACAT GAAAGACT GCC 
TGAGG
RIIBam5’ cloning S ATGGATCCACCATGGGTCGGGGGCTGCTCAG
RIINot3’ A TTGCGGCCGCCTATTTGGTAGTGTTTAGGGA
vGCR_seq S G GAAACATGACTGCAGACTG
vGCR_300 sequence S GGTATCTGCCTAAACTCGCT
VGCR300R A AGCGAGTTTAGGCAGATACC
T7 uni A T AAT ACG ACT CACT AT AGGG
p21_5’ S ACACCTT CCAGCTCCT GT AACAT ACT
p21 3’ A GAAACGGGAACCAGGACACAT
p27_5’ S CGGTGGACCACGAAGAGTTAA
p27_3’ A GGCTCGCCTCTTCCATGTC
p18_5’ S GCACTT GGCTGCCAAAGAAG
p18_3’ A TT CCGATGCCCCACATT G
p19_5’ S AGCCCGCACTGGATTCCT
p19_3‘ A CATCAGGCACGTTGACATCAG
O R F 26 5 ’ S GATTCCACCATTGTGCTCGAAT
O R F 26 3 ’ A CCCAGTT GCT GAGGCACG
O R F 50 5 ’ qRT-PCR S CACAAAAAT GGCGC AAGAT G A
O R F 50 3 ’ A TGGTAGAGTTGGGCCTTCAGTT
ORFK8_5’ S CAAGCTCGCTGTTGTCAACC
ORFK8_3’ A ATGACCGTTTCACAGACCGG
ORF 8.1_5’ S ATCCCTGTGGCGCTCCTAA
ORF 8.1_3’ A CGATACGTGGGACAATTGGC
GAPDH_5’ S GG AGT CAACGG ATTT GGT CGT A
GAPDH_3’ A GGCAACAATATCCACTTTACCAGAGT
ORF 73_5’ S TTGCCACCCACGCAGTCT
ORF 73_3’ A GGACGCATAGGTGTTGAAGAGTCT
vGPCR 5’ S GTGCCTTACACGTGGAACGTT
vGPCR_3’ A GGTGACCAATCCATTTCCAAGA
Rllsybr5’ S TTGACTGAGTGCTGGGACCAC
Rllsybr3’ A CT CACT GAAGCGTT CTGCCAC
Table 2.3 Primary antibodies for immunoprecipitation and immunoblotting
Antibody (clone/cat #) Isotype Company
cdk2 (M2) Rabbit IgG Santa Cruz Biotechnology CA, USA
cdk4 (C-22) Rabbit IgG Santa Cruz Biotechnology CA, USA
cdk6 (C-21) Rabbit IgG Santa Cruz Biotechnology CA, USA
Mdm2 Mouse IgG Santa Cruz Biotechnology CA, USA
FLAG (M1) Rabbit IgG Sigma
p-actin (Ab-1) Mouse IgG Oncogene
P21 (F-5) Rabbit IgG Santa Cruz Biotechnology CA, USA
p53 (FL393) Rabbit IgG Santa Cruz Biotechnology CA, USA
p27 (C-19) Rabbit IgG Santa Cruz Biotechnology CA, USA
cyclin A (H-432) Rabbit IgG Santa Cruz Biotechnology CA, USA
cyclin D2 (C-17) Rabbit IgG Santa Cruz Biotechnology CA, USA
SHP-2 (C-18) Rabbit IgG Santa Cruz Biotechnology CA, USA
SHP-1 (C-19) Rabbit IgG Santa Cruz Biotechnology CA, USA
Gab1 (CT) Rabbit IgG Upstate
AKT (9272) Rabbit IgG Cell Signaling Technology
pAKT (ser473) Rabbit IgG Cell Signaling Technology
pSHP2 (Tyr542) Rabbit IgG Cell Signaling Technology
pSHP2 (Tyr580) Rabbit IgG Cell Signaling Technology
PERK42/44 Rabbit IgG Cell Signaling Technology
ERK42/44 Mouse IgG Upstate
pFAK (Tyr397) Rabbit IgG Upstate
pTyr (PY99) Mouse IgG Santa Cruz Biotechnology CA, USA
FAK (4.47) Mouse IgG Upstate
BrdU-FITC Mouse IgG BD Pharmingen
p18 (M-168) Rabbit IgG Santa Cruz Biotechnology CA, USA
P19 (C-20) Rabbit IgG Santa Cruz Biotechnology CA, USA
p130 (AB-2) Mouse IgG Neomarker, CA
TGFp (AB-100-NA) Rabbit IgG R&D Systems
v-src (Ab-1) Mouse IgG Oncogene
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Table 2.4 Secondary antibodies for immunoblottinq
Antibody (clone/cat #) Isotype Company
Anti-mouse-HRP
(sc-2060)
IgG Santa Cruz Biotechnology CA, USA
Anti-rabbit-HRP (P0217) IgG DAKO
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CHAPTER 3:
3.0 Introduction
As discussed at length in the Introduction, KSHV vGPCR signaling properties 
and effects on cytokine production have been studied in various cell types, including 
common laboratory cell lines and primary endothelial cells. Unfortunately, little is 
known about the signaling properties of vGPCR in the haematopoietic cells relevant 
to KSHV-mediated disease. Haematopoietic cells serve as a reservoir and source of 
new KSHV virions in vivo; they therefore play a vital role not only in the KSHV 
lymphoproliferative disorders, but in KS as well. Furthermore, given the importance 
of cellular context to most signaling proteins and pathways, understanding of the 
contribution of vGPCR to KSHV-mediated pathobiology requires study of such cells. 
With this in mind, and just prior to my arrival at UCL, I derived KSHV-positive PEL 
cell lines engineered to express vGPCR in a controllable manner. Transient 
constitutive expression of vGPCR proved detrimental to PEL cells, so an inducible 
system was required. A single plasmid was designed to incorporate the sequences 
necessary for tight tetracycline inducibility along with the inverted terminal repeat 
(ITR) sequences from adeno-associated virus type 2 (AAV-2) to maximize the 
probability of stable integration (see Fig. 3.1 )(105, 106). During latent AAV-2 
infection, the AAV Rep protein binds DNA in or near the ITRs and mediates site- 
specific integration of the AAV genome into chromosome 19 of the human genome. 
However, even in the absence of Rep, the hairpin structure of the ITRs is thought to 
enhance random stable integration (85, 165, 213). Taking advantage of this
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property, I established inducible cell lines with one round of transfection followed by 
clonal selection for tight vGPCR inducibility. A PEL cell line was chosen as the 
parental line to express vGPCR in the context of natural KSHV infection and the 
presence of the entire viral genome. This allowed us to create a model for assessing 
vGPCR-mediated effects on other KSHV genes. Since vGPCR is an early lytic 
gene, latently infected PEL cell lines express very low levels (see Fig. 3.2). 
Therefore, using this inducible system, we can selectively induce vGPCR expression 
without treating the cells with agents that induce the entire lytic viral cycle.
The vGPCR-inducible PEL cell lines are ideal tools for studying vGPCR 
signaling in the context of KSHV infection. One of the first things I noticed when 
performing signaling studies on these cells was that the expression of vGPCR 
inhibited cell growth, without significant cell death as assessed by trypan blue 
staining (see Fig. 3.2B). This effect was unexpected given that vGPCR had been 
characterized as a viral oncogene in NIH3T3 cells and has growth- and 
angiogenesis-promoting effects in endothelial cells. I therefore sought to describe 
more completely this apparent vGPCR-mediated growth inhibition in these KSHV- 
infected haematopoietic cells.
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ITR
Amp
Pcmv
GFP
Pcmv
NeoR
ITSPtk
rtTA
Pcmv
Figure 3.1 . Map of pTruf-Tet, a single plasmid designed to allow tetracycline- 
mediated induction of transgenes cloned into the unique A/s/l site. ITR, inverted 
terminal repeat from AAV-2; Pcmv, CMV-derived promoter region; GFP, green 
fluorescent protein; pA, polyadenylation site from SV40; Ptre, tetracycline- 
responsive promoter; tTS, transcriptional silencer; rtTA, reverse tetracycline- 
responsive transcriptional activator; Neor, conveys neomycin resistance
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Figure 3.2. Establishment of doxycycline-inducible vGPCR-expressing 
PEL lymphoma cell lines. (A) Binding assay shows increased vGPCR 
protein expression with increasing doses of doxycycline. Cells were incubated 
with125l-GROa, and pellets were counted in a '/counter. The first two lanes 
verify that doxycycline has no independent effect on control BC-3 cells. (B) 
vGPCR expression slows the growth of PEL cells in culture. Cells were plated 
at 5 x 104 cells/ml with the doxycycline doses shown (in micrograms per 
milliliter) and counted daily by trypan blue exclusion. (Top) BC3.14 with 
increasing doxycycline doses and thereby increasing vGPCR expression. The 
percentage of dead cells does not vary between vGPCR-expressing and - 
nonexpressing cells. (Bottom) Control BC-3 cells incubated with 2 pg of 
doxycycline per ml show that doxycycline has no independent effect on cell 
growth. Shown is average of three independent experiments; error bars are 
omitted for clarity.
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CHAPTER 3: RESULTS
3.1 KSHV vGPCR signaling results in cell cycle arrest of PEL cells
The initial step in defining the apparent growth arrest caused by vGPCR was to 
examine the cell cycle profile of vGPCR-expressing PEL cells as compared with 
uninduced BC3.14 cells. The microtubule inhibitor nocodozole prevents mitosis and 
can be used to take a ‘snap-shot’ of one cell cycle. Figure 3.3A shows an example 
of DNA content analysis by propidium iodide staining of normally cycling BC3.14 
cells before and after 17 hours of nocodozole treatment. The first peak is labeled 
M1 and reflects the cells in G0/G1 with 2N DNA content. The plateau represents 
cells duplicating DNA in S phase, and the second, smaller peak is made up of cells 
in G2/M. Since mitosis is blocked by nocodozole, a pool of normally cycling cells 
will accumulate in G2/M over several hours. Figure 3.3B shows combined results of 
two such studies in BC3.14 cells with and without pre-incubation with doxycycline to 
express vGPCR. Cells were inoculated at identical concentrations and then 
incubated as normal for 48 hours with or without the doxycycline. Nocodazole was 
added for 17 hours and cell cycle position determined by propidium iodide staining 
and flow cytometric analysis (FCM). Results show that at baseline, BC3.14 cells 
progress rapidly through S phase and accumulate in G^M in the presence of 
nocodazole. However, when vGPCR is expressed, the cells arrest. Since the DNA 
profile does not change dramatically after the addition of nocodozole, this suggests 
that arrest is occurring throughout the cell cycle.
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Figure 3.3. KSHV vGPCR expression results in cell cycle arrest. (A) BC3 cells were 
exposed to 0.2 pg/ml nocodozole for 17 hours to block mitosis. Cells were then stained 
with propidium iodide and analyzed by FCM. The percentage of cells in G0/G1 is 
shown as M1 fraction. (B) BC3.14 cells were exposed to 2 pg/ml doxycycline where 
indicated for 48 hours to induce vGPCR expression. Cells were then stained with 
propidium iodide and analyzed by FCM as in (A). The percentage of cells in each cell 
phase are shown. Average of two independent experiments. *, p^).05 compared to 
corresponding point in ‘No Doxy’ panel.
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3.2 KSHV vGPCR inhibits entry into S-phase of PEL cells
To accurately assess the effect of vGPCR on the S-phase compartment over time, 
BC3.14 with or without vGPCR overexpression were incubated with 
bromodeoxyuridine (BrdU), plated, then stained with anti-BrdU antibody and 
counted. Figure 3.4A shows a vGPCR-induced exit from S phase from 50% to less 
than 20%. This decrease if greater than that seen in Figure 3.3B and may be 
explained by observer bias. Figure 3.4B graphically represents multiple such 
experiments using two different doses of doxycycline over five days. As suspected, 
a very low dose of doxycycline had no effect. However, full dose doxycycline 
resulted in a marked inhibition of S-phase by 72 hours. Groa is a known vGPCR 
agonist and we noted that downstream signaling effects of vGPCR are easer to 
detect in the presence of Groa (38). However, in this case, the phenotypic effect of 
cell cycle arrest was not appreciably enhanced by Groa. This simply attests to the 
strong constitutive activity of vGPCR and is not unexpected.
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Figure 3.4. KSHV vGPCR inhibits S-phase entry in PEL cells. (A)
BC3.14 cells were exposed to doxycycline where indicated for 48 hours 
and then fixed to glass slide by cytocentrifugation. Cells were incubated 
with BrdU for 6 hours followed by FITC-conjugated anti-BrdU. (B) BC3.14 
cells were exposed to doses of doxycycline as shown for up to 120 hours. 
Cells were re-fed every 48 hours to prevent density-induced arrest. BrdU 
staining was performed at each time point as described above. Cells were 
manually counted and average of three experiments shown. Error bars
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3.3 vGPCR causes a p53-independent transcriptional upregulation of p21cip 
in PEL cells
Cell cycle progression is regulated through a precise temporal activation of cyclin 
dependent kinases (Cdks). Two classes of Cdk inhibitors (CDI) are crucial to this 
ordered Cdk activation and include the CIP/KIP and INK4 families (246). Of note, 
endogenous p16INK4a expression is not detected in PEL cells due to either 
deletion or hypermethylation; BC-3, the parent line used in the experiments here is 
an example of p16 deletion. It has also been shown to be Rb negative, a 
characteristic of some but not all PEL lines (212). Furthermore, PEL cells do not 
display c-myc rearrangements, or alterations in p53, bcl-2 or ras (45). Therefore, we 
initially focused our efforts on the CIP/KIP CDI family.
Using Western blotting and quantitative reverse transcriptase-PCR (qRT- 
PCR), we examined the effect of vGPCR signaling on p21cip and p27kp, CDIs known 
to inhibit the S-phase cyclins, E and A. Figure 3.5A shows that doxycycline-induced 
expression of vGPCR results in increased protein levels of both p21 and p27. 
Supporting the specificity of this vGPCR-mediated effect is that Groa results in 
slight enhancement of protein accumulation when added to vGPCR-expressing 
cells but has no independent effect. It is possible that accumulation of p21 and p27 
merely reflect an enhanced accumulation of cells in G0/G1. We therefore used 
qRT-PCR to look for transcriptional upregulation of the CDIs. Figure 3.5B shows a 
clear increase in p21 message that would suggest a causal effect on cell cycle 
arrest rather than a secondary accumulation. Changes in p27kip transcript are not 
significant in the absence of Groa stimulation. Since cell cycle arrest does not
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require the addition of a vGPCR agonist (see Figure 3.3), we conclude that vGPCR 
signaling mediates an increase in p21 but that increases in p27 are a secondary 
effect of cell cycle arrest and not likely to be an important part of the vGPCR 
signaling pathway. Furthermore, using qRT-PCR we assayed for p18 and p19, but 
found no detectable effect of vGPCR on the INK family of CDIs (Fig. 3.6A). As 
mentioned above, BC3 cells, the parent line of BC3.14, have been shown to 
express no p16 (212) and our experiments confirmed this for BC3.14 (data not 
shown).
Increases in p21 can be either dependent or independent of the tumor 
suppressor p53 (3, 96, 136, 297). We therefore assessed the vGPCR-mediated 
effect on p53 in our PEL cell line. Figure 3.6B shows that despite prolonged 
incubation with doxycycline, the resultant vGPCR expression did not result in 
accumulation of p53 or mdm2 as would be expected with p53 activity (15, 289). 
Furthermore, luciferase reporter assays using a p53-responsive promoter show 
some decrease in p53 activity (Fig. 3.6C). The cause of this decrease is unclear 
but certainly argues against a p53-mediated increase in p21.
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Figure 3.5. KSHV vGPCR upregulates p21 and p27. (A) BC3.14 cells 
were exposed to 2 ng/ml of doxycycline for length of time shown in hours. 
Western blot shows vGPCR-dependent increases in p21 and p27 over 96 
hours. Shown is one of three independent experiments. (B) Quantitative RT- 
PCR shows vGPCR-dependent transcriptional regulation of p21 and to a 
lesser extent, p27. Gro<x(100 nrp)a vGPCR agonist, is included to assure 
specificity of observed effects. Average of two independent experiments 
each done in duplicate is shown. *, significant increase over baseline p ^  
0.05.
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Figure 3.6 KSHV vGPCR-induced cell cycle arrest is not mediated by p18, p19, or 
p53. (A) Quantitative RT-PCR shows lack of vGPCR-dependent transcriptional 
regulation of p18 and p19 using same cDNA as Fig 3.5. Grc>(x(100 nm) is included to 
assure specificity of observed effects. Average of two independent experiments each 
done in duplicate is shown. (B) BC3.14 cells were exposed to doxycycline for the 
specified length of time to induce vGPCR, after which protein lysates (30 ^g) were 
loaded onto 12% SDS-PAGE gels and probed for p53 and mdm2. Shown is one 
representative of three independent Western blot experiments. (C) BC3.14 cells were 
transfected with p53-TA-luc, a commercially available p53 reporter construct. 
Transfected cells were then divided and incubated with doxycycline (2 jig/ml for 48 
hours), GROa (100nM), or without additives as shown. Protein lysates were harvested 
and equal amounts assayed. Cells were divided after transfection, so no further control 
for transfection efficiency was performed. As expected, vGPCR expression has no
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3.4 vGPCR signaling inhibits Cdk2, but not Cdk4 or Cdk6 activity
Having identified p21 as the CDI responsible for vGPCR-mediated cell cycle arrest, 
we next investigated the level of various cyclins and, more importantly, the activity 
of the relevant Cdks. Cdks are expressed at more or less constant levels 
throughout the cycle but are regulated through the synthesis and degradation of the 
cyclins (181). The D-type cyclins are short lived and assemble with Cdk4 or Cdk6 
in G1 in the presence of ongoing mitogenic stimuli (119). Cyclin E peaks at the 
transition from G1 to S phase followed by cyclin A during S phase. Both these 
cyclins activate Cdk2 (152). Although multiple approaches failed to accurately 
quantify cyclin E levels in these cells, Western blotting in Figure 3.7A shows that 
ongoing vGPCR expression results in decreased levels of cyclin A and cyclin D2. 
This decrease in levels of the G1 and S phase cyclins are consistent with the data 
in Figure 3.3 showing cell cycle arrest. However, a more definitive functional assay 
of the cyclin-dependent kinases was performed (148). Using the C-terminus of 
retinoblastoma protein (Rb) as a substrate, we assayed the kinase activity of Cdk2, 
4 and 6 (Figure 3.7B). Although vGPCR had no effect on Cdk 4 or 6, it produced a 
marked reduction in Cdk2 activity. This is in keeping with the known inhibitory 
effects of p21 on Cdk2. The effect of p21 on Cdk4/6 is more complex with some 
models showing inhibition but others arguing that the Cdk/cyclinD interaction with 
p21 is also important to sequester p21 away from the Cdk2/cyclin E complex (245).
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Figure 3.7. KSHV vGPCR causes decreased levels of cyclin A, D2 complexes 
and decreased cdk2 kinase activity. (A) To express vGPCR, BC3.14 cells were 
exposed to 2 pg/ml doxycycline for the time shown in hours. Protein lysates were run 
on 10% SDS-PAGE gels and probed with appropriate antibodies. (B) BC3.14 cells 
were incubated for 48 hours with doxycycline and then lysed in kinase buffer. 
Antibodies were then used to immunoprecipitate each kinase as indicated. After 
resuspension in kinase buffer, the substrate GST-pRb (C term) was added along with 
[y_32P] ATP. Phosphorylated product was detected by autoradiography after 
separation on a 12% SDS-PAGE gel (top row). 10% of the protein input for the IP was 
used to Western blot for each kinase (bottom row). One representative of three 
independent experiments is shown.
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The retinoblastoma family of proteins includes pRb, p107 and p130 (for 
review, see (108)). The phosphorylation status of these proteins is moderated 
during cell cycle as well as at the cell cycle entry and exit transitions (33, 56). They 
are tumour suppressors and negatively regulate cell cycle progression when 
hypophosphorylated. However, when pRb is phosphorylated by the cyclin-D/cdk 
complex, this releases E2F from repression which activates transcription of cyclins 
E and A which in turn, phosphorylate pRb at the G1/S transition. Inhibition of cyclin 
E or Cdk2 prevents transition to S-phase and induces G1 arrest (199, 205). Since 
we had observed a vGPCR-mediated Cdk2 inhibition, we therefore assessed its 
effects on the pRb family. In agreement with published data, we found no 
expression of pRb in our PEL cell line BC3 whereas it is expressed in various other 
PEL lines (Fig. 3.8A). However, p130 and p107 are also able to mediate cell cycle 
arrest via interactions with E2F and the cyclins, so we performed Western blots to 
ascertain whether phosphorylation status or total protein levels varied consistently 
due to vGPCR expression. Unlike pRb, the levels of p130 and p107 vary with the 
cell cycle. When cells are forced to exit the cell cycle, p130 levels rise sharply 
coinciding with accumulation of p130/E2F complexes (134, 172). Although p130 did 
not vary as detected by Western blots, p107 levels generally seemed to increase 
with vGPCR-mediated arrest, but the results were inconsistent and we could make 
no firm conclusions (Fig. 3.8B). Likewise, phosphorylation status as judged by band 
shifts was not eviedent (data not shown).
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Figure 3.8. KSHV vGPCR has no consistent effect on levels of the pocket 
proteins p130 and p107. (A) Protein lysates of several PEL lines were used 
in Western blotting to assess protein levels of the pocket proteins pRb, p130, 
and p107. (B) BC3.14 cells exposed to doxycycline as shown were subjected 
to Western blotting for p130 and p107.
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CHAPTER 4:
4.0 Introduction
Herpesviruses manipulate and rely on certain host cell cycle functions for 
persistence and replication. Unlike small DNA tumour viruses, herpesviruses 
encode their own DNA polymerase and generally prevent progression to S-phase 
during replication. However, certain viral products activate some cell cycle 
regulatory pathways that would normally promote cell cycle progression and 
inhibition of these pathways inhibits viral replication. There exists, therefore, a 
general theme that herpesviruses have evolved to block certain cell cycle functions 
while relying on others. For example HSV-1 IE gene expression requires Cdk 
activity (128). However, HSV-1 also can mediate a G1 cell cycle arrest to block 
host cell DNA synthesis (83). Like HSV, CMV can effect a cell cycle arrest and 
does so via at least two distinct viral products, the tegument protein UL69 and the 
immediate-early gene product IE2 (282). However, CMV infection also promotes 
cyclin E levels and cyclin E-associated kinase activity that appears to be required 
for replication (30). The induction of EBV replication also arrests cell cycle 
progression in spite of elevated S-phase cdk activity and consequent 
hyperphosphorylation of pRb (29, 143, 144).
My results in Chapter 3 showing that vGPCR induces a cell cycle arrest 
could possibly indicate a change from latent to lytic viral life cycle. After all, vGPCR 
is an IE gene and it is therefore well positioned transcriptionally to affect the latent- 
to-lytic switch. However, we also found that vGPCR inhibits Cdk2 and as
107
mentioned above, Cdk2 is necessary for EBV and CMV replication. We therefore 
wanted to assess vGPCR’s effect on the chemical induction of the latent-to-lytic 
switch in our PEL cell line BC3.14.
CHAPTER 4: RESULTS
4.1 KSHV vGPCR inhibits chemically-mediated lytic gene induction
Having shown that vGPCR overexpression inhibits Cdk2, we used qRT-PCR to 
quantitate the transcription of KSHV ORF 50 and ORF 26 in chemically induced 
BC3.14 cells in the presence or absence of vGPCR expression. ORF 50 is an IE 
transactivator gene of the y-herpesviruses that is necessary and sufficient to drive 
lytic replication in KSHV, Rhesus rhadiovirus, and murid herpesvirus-68. Deletion 
or inhibition by a dominant-negative mutant will prevent lytic replication. ORF 26 is a 
late lytic gene that encodes a capsid protein. Measuring the induction of these lytic 
genes is a surrogate for successful lytic replication. Both butyrate and TPA induce 
PEL lines to produce new virions, although levels of class II and III transcripts vary 
depending on the stimulus (296). Using standard doses of butyrate and TPA we 
found that induction of both ORF 50 and ORF 26 transcripts was markedly reduced 
in BC3.14 cells that were made to express vGPCR prior to induction (Figure 4.1). 
The effect was most dramatic with TPA and high dose butyrate. Since vGPCR is 
itself a lytic gene and chemically inducible, we compared the levels of vGPCR 
transcript achieved with doxycycline induction versus chemical induction. We felt it 
important to do so since vast overexpression of exogenous signaling proteins can
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force otherwise unnatural associations and downstream effects. We found that at 
48 to 96 hours of doxycycline induction, levels of vGPCR transcript were 
comparable to those induced by standard TPA and butyrate doses at 48 hours; 
doses known to bring about successful virion production (Figure 4.2). Although we 
have never seen a phenotypic effect of doxycycline on control cell lines (i.e. BC3), 
we also performed control experiments on BC3 to ensure that doxycycline was not 
having an unexpected effect on the chemical induction of ORF 50 or ORF 26. 
Indeed, doxycycline had no independent inhibitory effect on ORF 50 or ORF 26 
when assayed by qRT-PCR; curiously however, there was a trend of higher 
butyrate-induced levels in the presence of doxycycline (Figure 4.2B). The reason for 
this is unclear but does not detract from the data presented in Figure 4.1.
Since ORF 50 is essential to the KSHV latent-to-lytic switch, it seemed likely 
that inhibition by vGPCR reflected a global inhibition of lytic gene transcription. 
However, a preferential inhibition of only certain lytic genes could lead to an 
‘abortive’ or incomplete lytic program. To assess whether vGPCR-mediated 
inhibition of the chemical induction of ORF 50 and ORF 26 was specific to these 
lytic genes, primers for qRT-PCR were designed and optimized for the lytic ORFs 
K8 and K8.1. ORF K8.1 is a late transcript encoding a structural glycoprotein, 
while K8 is an IE transcript that encodes a basic region-leucine zipper protein of 237 
aa that homodimerizes; K8 shows significant similarity to the EBV immediate-early 
protein Zta. Figure 4.3 shows that vGPCR expression prior to chemical induction 
also prevented the transcription of K8 and K8.1. Although all lytic genes have not
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Figure 4.1. KSHV vGPCR expression inhibits lytic gene induction by TPA 
and butyrate. BC3.14 cells were treated for 48 hours with 2 f.ig/ml of doxycycline 
where indicated to express vGPCR, after which cells were also exposed to 
butyrate (1 mM or 2 mM) (A) or TPA (20 ng/ml)(B) to induce KSHV lytic gene 
transcription. qRT-PCR was performed for ORF 50 and ORF 26 message.
Results are normalized to untreated cells (lane 1). Shown in both (A) and (B) are 
two independent experiments each done in duplicate. *, significant increase over 
baseline p<0.05; **, significant decrease from maximum induction, p<0.05.
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Figure 4.2. Doxycycline induction of KSHV vGPCR in BC3.14 cells results in 
increases in vGPCR message similar to levels obtained with lysis-inducing 
chemicals. (A) BC3.14 cells were treated for 48 hours with TPA (20 ng/ml), 
butyrate (1 mM and 2 mM), or 2 ng/ml of doxycycline (48 and 96 hours). 
Quantitative RT-PCR was then done using primers for KSHV vGPCR. Results 
were normalized to untreated cells in lane 1. (B) Table summarizes quantitative 
RT-PCR results for ORF 50 and ORF 26 in BC3 cells treated for 48 hours with 
butyrate (2 mM), TPA (20 ng/ml), doxycycline (2 ng/ml) or combinations as 
shown. Results shown are average of two independent experiments and indicate 
that doxycycline has no independent negative effect on induction of ORF 50 or 
ORF 26.
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Figure 4.3. vGPCR expression prevents chemical induction of KSHV lytic genes 
K8.1 and K8. BC3.14 cells were treated for 48 hours with 2 ng/ml of doxycycline 
where indicated to express vGPCR, after which cells were also exposed to butyrate (1 
mM or 2 mM) (A) or TPA (20 ng/ml)(B) to induce KSHV lytic gene transcription. qRT- 
PCR was performed for K8.1 and K8 message. Results are normalized to untreated 
cells (lane 1). Shown in both (A) are two independent experiments each done in 
duplicate. (B) and (C) were performed once in duplicate and given negative results 
were not repeated.
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been tested, these results strongly suggest that vGPCR has a global inhibitory 
effect on KSHV lytic gene transcription.
4.2 KSHV vGPCR inhibits lytic activation via inhibition of Cdk2
As discussed, Cdk2 activity is necessary for both EBV and CMV replication. We 
therefore assessed specifically whether the vGPCR-induced inactivation of Cdk2 
could be at least partially responsible for the decrease in chemically induced 
transcription of ORF 50 and 26. Using lentiviral transduction, we infected BC3.14 
cells with either a Cdk2 dominant negative (DN) construct or a reverse Cdk2-DN 
sequence as a control (272). Cells were incubated with butyrate; ORF 50 and 26 
transcripts were quantified by qRT-PCR. Figure 4.4 shows that the Cdk2 dominant 
negative caused an approximately 50% reduction in both transcripts. Of note, these 
data allow us to conclude that it is the vGPCR-induced inhibition of Cdk2 that 
results in inhibition of ORF50 and ORF26 transcripts, strongly suggesting an 
impairment of successful lytic replication.
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Figure 4.4. Cdk2 activity is necessary for full chemical induction of 
KSHV lytic genes. BC3 cells were infected with lentivirus expressing 
the Cdk2 dominant negative coding sequence in either forward or 
reverse (control) orientation. 72 hours later, cells were treated with 1 mM 
butyrate for 48 hours as indicated. Quantitative RT-PCR was performed 
for ORF 50 (top panel), and ORF 26 (lower panel). Figure represents 
two independent experiments each done in duplicate. *, significant 
increase over baseline p<0.05; **, significant decrease from maximum 
induction. o<0.05.
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CHAPTER 5:
5.0 Introduction
KSHV vGPCR is known to signal broadly via multiple Ga subtypes and via several 
growth-related tyrosine kinase pathways. However, nothing is yet known about the 
vGPCR’s effects on the protein tyrosine phosphatases (PTPs) which are just as 
crucial to extracellular signaling as PTKs and are increasingly the target of 
pharmacologic inhibitor design. As discussed in Chapter 1.13, the ITIM motif is a 
consensus sequence that when tyrosine-phosphorylated can bind one or more of 
the PTPs, thereby causing a conformational change in the PTP and releasing basal 
auto-inhibition of the phosphatase catalytic domain. A receptor that contains a 
cytoplasmic ITIM motif is therefore a valid candidate as an inhibitory receptor and 
an activator of the PTPs. We have identified an ITIM motif at the junction of the 
seventh transmembrane domain and the cytoplasmic tail of the KSHV vGPCR. 
Although it is still debatable whether GPCRs directly bind to PTPs generally, there 
is one report that the bradykinin B2 receptor binds SHP-2 via an ITIM at the 
proximal cytoplasmic tail (LVYVIV) (71). Bradykinin stimulation transiently 
increases the association of this GPCR with SHP-2 and enhances its phosphatase 
activity. Although SHP-2 is generally thought to play a positive role in growth factor 
signaling, the authors show that SHP-2 activation is required for the anti-mitogenic 
effect bradykinin has on proliferating renal mesangial cells.
Although the KSHV vGPCR has mitogenic effects in standard transformation 
assays and enhances the longevity of HUVECS, we have noted that overexpression
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of vGPCR is detrimental to some cell types. Although this may be a function of 
expression levels of vGPCR, it is possible that as in the case of the bradykinin 
receptor, vGPCR may have both positive and negative effects on cell growth; the 
cell cycle arrest in PEL cells described in Chapter 3 is an example of the latter. This 
possibility combined with the presence of an ITIM motif requires that vGPCR be 
further investigated for a possible association with the PTPs. Although we 
hypothesize that the vGPCR ITIM facilitates an interaction with one or more of the 
PTPs, it is possible that such an interaction could occur in an ITIM-independent 
manner. For example, Feng et al show that despite the presence of an ITIM in the 
3rd cytoplasmic loop, the angiotensin II AT2 receptor activates SHP-1 in an ITIM- 
independent fashion via a Gas subunit (81). Furthermore, it must also be kept in 
mind that the selectivity of various ITIM motifs for the different SH2-containing PTPs 
is not wholly understood. Therefore, receptor interaction with one SHP subtype 
cannot be generalized to other subtypes; each must be individually investigated.
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CHAPTER 5: RESULTS
5.1 KSHV vGPCR activity phosphorylates SHP-2 at Y542 but not Y580.
SHP-1 and SHP-2 undergo tyrosine phosphorylation of tyrosine residues in their C- 
terminal tails (see Fig. 5.1). Whether this phosphorylation regulates phosphatase 
activity or merely enhances the role of these PTPs as scaffolding molecules is 
controversial. Lorenz et al. saw no change in phosphatase activity upon SHP-1 
phosphorylation at Y536 and Y564 in CD4- or CD8-stimulated T cells (162). 
Moreover, they hypothesized that the phosphorylated tyrosines could bind to the 
SH2 domains of Grb2, a molecule now known to be recruited by SHP-1 (177). On 
the other hand, others have shown that phosphorylation of the homologous 
tyrosines on SHP-2 does indeed increase phosphatase activity (80). Since both 
SHP-1 and SHP-2 can auto-dephosphorylate, the phosphorylation status of the C- 
terminal tyrosines is labile and notoriously difficult to study. Elegant work using 
non-hydrolysable mimics of phosphotyrosine in place of the wild-type residues, 
shows that SHP-2 phosphatase activity is slightly increased and SHP-1 activity 
markedly increased by these substitution (80, 298). There is no thorough 
mechanistic investigation of how phosphorylation of C-terminal tyrosines could 
induce phosphatase activity. However, the above authors hypothesize that the 
phosphotyrosyl residues bind intramolecularly to the SH2 sites thereby causing the 
necessary allosteric switch. Regardless of their exact role, the high degree of 
evolutionary conservation suggests that the C-terminal phosphotyrosyl residues 
place an important role in SHP-1/2-mediated signaling.
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Given the ubiquitous nature of SHP-2 and the availability of phospho-specific 
antibodies, we chose to start our investigation of vGPCR-mediated effects on PTPs 
by evaluating whether vGPCR increases C-terminal tyrosine phosphorylation of 
SHP-2. Using increasing doses of a vGPCR expression construct, we found that 
vGPCR enhanced phosphorylation of SHP-2 Y542 in both NIH 3T3 and HEK 293 
cells (Fig 5.2). No change in baseline phosphorylation of Y580 was seen. Since 
many investigators study the PTPs under serum starvation conditions to decrease 
baseline activation, we did the same; the same vGPCR-induced effect was seen 
(data not shown). For further studies we used HEK 293 for ease of manipulation 
and transfection.
—(SH2)— (
SHP-1 Q514---- ^
SHP-2 H520
Figure 5.1. Schematic of SHP-1 and SHP-2 C- 
terminal tails. Adapted from Jones, M (2005) Cell Sig 
(17):p1323
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Figure 5.2. KSHV vGPCR expression results in phosphorylation 
of SHP-2 at Y542, but not Y580. (A) NIH 3T3 cells or HEK 293
cells were transfected with increasing amounts of pcKSHV-vGPCR. 
After 48 hours, cells were lysed in RIPA buffer and Western blotting 
performed for Y542-phosphorylated SHP-2. Blots were then stripped 
and re-probed for total SHP-2. (B) HEK 293 lysates were also 
probed for Y580 phosphorylation. Shown are representative blots of 
three independent experiments.
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5.2 The vGPCR Y142F ITIM mutant properly expresses and localizes to the 
plasma membrane
To delineate the signaling events responsible for vGPCR-mediated SHP-2 
phosphorylation, we took two simultaneous directions. One was to evaluate the 
necessity of the ITIM motif by creating a mutant vGPCR in which the tyrosine of the 
ITIM is replaced by phenylalanine (herein referred to as AITIM). The other was to 
assess the classical mode of signaling by GPCRs, namely via coupling to 
heterotrimeric G proteins (section 5.3). Initial development and analysis of the AITIM 
mutant is described in this section, but will be addressed further in sections 5.4 and
5.5.
Occasionally, GPCR mutants do not properly express and/or localize to the 
plasma membrane. Since there is no readily available antibody to KSHV vGPCR, 
we engineered amino-terminus FLAG-tagged wild-type vGPCR and AITIM 
constructs. As shown by immunofluorescence in Figure 5.3A, the mutant receptor 
properly localizes to the plasma membrane. Flow cytometry (FCM) shows that the 
mean fluorescence (MF) of cells transfected with equal amounts of wild-type and 
mutant vGPCR are equal, confirming that the AITIM mutant is expressed as 
efficiently as the wild-type.
As a functional assay of the newly designed AITIM mutant, it was compared 
to wild-type vGPCR in its ability to stimulate NFKB-mediated transcription of a 
luciferase reporter construct (Fig. 5.3B). Despite equal expression, the AITIM 
mutant activated NFkB to approximately 50% of the wild-type. Of note, the amino- 
terminal FLAG epitope tag does not appreciably interfere with constitutive NFkB
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activation by the wild-type or AITIM vGPCR. Binding studies to assess interference 
with ligand binding to the extracellular amino terminus were not done since the 
FLAG-tagged constructs were used for IP studies in the absence of any exogenous 
ligand. Further characterization of the AITIM mutant will be shown in later figures.
5.3 vGPCR phosphorylates SHP-2 via a Gaq-Src axis
Although the ITIM domain could possibly be involved with the vGPCR-mediated 
phosphorylation of SHP-2, we also performed studies to determine if the more 
classical G protein activation by the vGPCR could be responsible. vGPCR is known 
to couple to both Gai and Gaq subtypes of G protein. In Figure 5.4A, pertussis 
toxin (200 ng/ml), a pharmacologic inhibitor of Gai subunits was added to cell 
culture 12-17 hours prior to making protein lysates. These experiments show that 
Gai subunits are not necessary to either baseline or vGPCR-induced SHP-2 
phosphorylation. In some studies ERK is shown to be upstream of SHP1/2 
activation and in others downstream. We used a pharmacologic inhibitor of ERK, 
PD98059, in standard doses (25 pm) and found that ERK activity is not required for 
SHP-2 phosphorylation by vGPCR. As mentioned above, there are reports that Src 
kinase family members are required to activate SHP1/2. Furthermore, we and 
others have shown that vGPCR can activate Src family members (37). Therefore, 
PP2 (5 pm), a specific pharmacologic inhibitor of Src, was also assessed for its 
effect. Src inhibition resulted in dramatic inhibition of both baseline SHP-2 Y542 
phosphorylation and vGPCR-induced phosphorylation. To verify the PP2 data, a 
commercially available dominant-negative construct of Src was also evaluated and
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Figure 5.3. The vGPCR-AmM mutant properly localizes to cell 
membrane and is expressed at similar levels as wild-type vGPCR, 
but is less efficient at activating NFk B. (A) HEK 293 cells were 
transfected with equal amounts of plasmid expressing either FLAG- 
vGPCR or the FLAG-vGPCR AITIM mutant. After 48 hours, cells were 
stained with anti-FLAG antibody and DAPI to stain nuclei. Cells were 
also evaluated by FCM and mean fluorescence (MF) was very similar 
for wt and mutant vGPCR. (B) HEK 293 cells were transfected with 
constructs as indicated and NFKB-mediated expression of luciferase 
measured at 48 hours post-transfection. Bars indicate S.D. of three 
independent experiments.
found to result in inhibition of vGPCR-mediated phosphorylation, with no 
appreciable effect found on baseline phosphorylation (Fig. 5.4C). This is not 
surprising in that the dominant-negative construct would not be expected to be as 
potent as PP2 given issues of transfection efficiency and expression of the former. 
Nonetheless, the combined PP2 and dominant-negative data strongly support the 
involvement of Src in this pathway.
Since we saw no evidence for a Gai requirement, we sought to determine if 
Gaq coupling was necessary to vGPCR’s effects on SHP-2. Unfortunately there is 
no reliable inhibitor of Gaq subunits. Therefore, most investigators rely on gain-of- 
function experiments using a constitutively-active mutant, Gq(Q209L), to obtain 
indirect evidence of a Gaq requirement (288). Figure 5.4B shows that despite the 
lack of vGPCR expression, the constitutively-active Gaq subunit is sufficient to 
cause phosphorylation of SFIP-2 at Y542. To further support a role for Gaq as 
opposed to Gai, a possible requirement of the Py subunit was also evaluated. 
Although both Gai and Gaq G proteins can signal via their Py subunits, Gai is more 
dependent on the Py subunit and the a  subunit has weak signaling potential of its 
own. A commonly used approach to inhibit py signaling is to co-express the G 
protein a  subunit of retinal transducin (aT) as a scavenger of Py subunits (79). 
Figure 5.5A shows that aT has no effect on SHP-2 phosphorylation. As a positive 
control to show that the aT subunit can be expressed and Gai coupling is 
necessary to certain vGPCR functions in this cell type, an N F kB  reporter assay was
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performed in 5.5B. By scavenging py subunits, vGPCR-mediated N F k B activation 
was decreased by approximately 60%.
5.4 The vGPCR does not activate SHP-2 phosphatase activity and the ITIM 
motif is not required for SHP-2 phosphorylation
The data in Figures 5.4 and 5.5 and the fact that vGPCR activates Src, 
argues for a vGPCR-Gaq-Src axis as responsible for SHP-2 phosphorylation in our 
model. Since expression of the constitutively active Gq(Q209L) results in the 
phosphorylation of SHP-2 in the absence of vGPCR, it would be hard to argue that 
the vGPCR ITIM motif is necessary. Moreover, given that interaction with an ITIM 
motif activates the PTPs, it would be expected that any direct interaction of SHP-2 
with the vGPCR ITIM would enhance SHP-2 phosphatase activity. We therefore 
assessed this activity by immunoprecipitating SHP-2 after transfection with vGPCR, 
mutant vGPCRs, or Gq(Q209L). Immunoprecipitated enzyme was incubated with a 
phosphorylated peptide and free phosphate release measured. As shown in Figure
5.6, neither vGPCR, the AITIM mutant or the constitutively-active Gaq subunit 
activated SHP-2 phosphatase activity. Of note, we also included a vGPCR mutant 
in which the VRY motif in the second cytoloop was changed to ALY (AALY). This 
VRY motif is a variant of the very well conserved DRY motif which is crucial to G 
protein coupling with GPCRs.
Together, the data presented in Figures 5.5 and 5.6 support a signaling 
pathway as shown in Figure 5.7. Despite a lack of phosphatase activity, the 
vGPCR-induced SHP-2 phosphorylation may well be required for promoting SHP-2 
scaffolding functions. This possibility will be discussed in Chapter 7.
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Figure 5.4. vGPCR-induced SHP-2 phosphorylation is Gaq- and Src-dependent but 
ERK independent. HEK 293 cells were transfected with either control plasmid, vGPCR (A 
and C), or the constitutively active Gaq mutant Gq(Q209L) (B). After 36 hours, inhibitors 
were added where shown (A and B). In panel (C), Src dominant negative construct was 
co-transfected as shown. Protein lysates were made 48 hours post-transfection and 
Western blot performed for Y542-phosphorylated SHP-2. Blots were stripped and re­
probed for total SHP-2. PTX, pertussis toxin (200pg/ml), PP2 (5 pM), PD, PD98059 (25
pM ).
125
£  £
pcDNA3.1 vGPCR
p542-Shp2
tShp2
B  1 4 0  
0,120 
$100  
£  8 0  
3  6 0
i«
a: 20 
0
Figure 5.5. KSHV vGPCR-mediated phosphorylation of SHP-2 is not 
dependent on py subunits. (A) HEK 293 cells were transfected with 
vGPCR or control plasmid as shown with or without a-transducin subunit. 48  
hours post-transfection, protein lysates were subjected to Western blotting 
for Y542-phosphorylated SHP-2. Blots were then stripped and re-probed for 
total SHP-2. (B) HEK 293 cells were co-transfected with NFicB-luciferase 
reporter construct and either vG PCR or control plasmid; a-transducin 
subunit was also transfected where indicated. 48 hours post-transfection, 
lysates were harvested and luciferase activity determined. All samples were 
also transfected with TK-Renilla construct to control for transfection 
efficiency. Values are normalized to control point. Bars represent S.D.
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Figure 5.6. KSHV vGPCR does not affect SHP-2 phosphatase 
activity.
HEK 293 cells were transfected with wt vGPCR, mutant vGPCR, or 
constitutively active Gaq along with SHP-2 expression construct. 48  
hours post-transfection, lysates were immunoprecipitated with anti- 
SHP-2 antibody and incubated with SHP-2 substrate. Release of free 
phosphate was measured by malachite green assay as described in 
Materials and Methods. Results were normalized to control point
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Figure 5.7 Schematic of vGPCR-mediated SHP2 phosphorylation
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5.5 The vGPCR mutant AITIM is unable to fully activate ERK or to 
phosphorylate SHP-2 due to inefficient Src activation
Although the data above do not support a role for the vGPCR ITIM in SHP-2 
phosphorylation, it is clear that the AITIM mutant does not function as well as the 
wild-type receptor. This is demonstrated by its inefficient NFkB activation shown in 
Figure 5.3B. We felt further characterization of this interesting new mutant was 
warranted. Figure 5.8A shows that although AITIM expression results in some 
increase in SHP-2 phosphorylation, it is less than wild-type vGPCR. As expected 
this is also the case with the negative control, AALY, which cannot properly couple 
to G proteins. An inability of AITIM to fully activate ERK is also evident. Of interest 
we have also found that vGPCR signaling results in phosphorylation of focal 
adhesion kinase (FAK). Although the study of vGPCR’s effects on FAK and cell 
morphology is the subject of other ongoing studies, it is not addressed specifically in 
this thesis; we simply include the data here as further evidence that AITIM fails to 
signal properly.
Since we have shown that Src is required for SHP-2 phosphorylation, we 
hypothesized that the AITIM signaling defect could be due to inefficient Src 
activation. The immunoprecipitation study shown in Figure 5.8B shows that AITIM 
does not promote a Src-SHP-2 association as does the wild-type vGPCR. 
Furthermore, Figure 5.8C shows that whereas Src inhibition affects NFKB-mediated 
transcription by wild-type vGPCR and constitutively-active Gq(Q209L), it has no 
inhibitory effect on A ITIM-mediated activation. Although just a pilot experiment 
currently being further optimized, the Src-kinase assay shown in Figure 5.9
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Figure 5.8. The vGPCR-AITIM mutant is less efficient at phosphorylating SHP-2 and ERK 
compared to wt vGPCR due to decreased activation of Src. (A)HEK 293 cells were 
transfected with wt vGPCR, mutant vGPCR or constitutively active Gq(Q209L) as shown. 48 
hours after transfection, Western blots for phosphorylated SHP-2, FAK, or ERK were 
performed as indicated. Blots were then stripped and re-probed for total enzyme levels in each 
case. Shown is representative of three independent experiments. (B) HEK 293 cells were 
transfected as above and lysates immunoprecipitated with anti-Src antibody, followed by 
immunoblotting for SHP-2. Blots were stripped and probed for Src to show similar levels of 
immunoprecipitated protein, HC, heavy chain. (C) HEK 293 cells were transfected with an 
NFicB-luciferase reporter gene construct along with expression constructs as indicated on x- 
axis, +/- Src dominant-negative construct. Luciferase assays were performed 48 hours post­
transfection. Shown is average of two separate experiments done in duplicate. Bars indicate
seems to show slightly less auto-phosphorylation of endogenous Src in HEK 293 
cells transfected with the AITIM mutant as opposed to the wild-type vGPCR. 
Together these data strongly suggest that the AITIM mutant is unable to completely 
activate Src. Furthermore, lack of Src induction would also explain poor ERK 
activation by AITIM as evidenced by the Western blot in Figure 5.10 which shows 
that the Src dominant-negative construct interferes with vGPCR-induced ERK 
activation. Since we found that both ERK and NFkB activation by vGPCR require 
Src activity, we assessed whether ERK was necessary for NFkB activation in these 
cells. Such was not the case in our previous studies with haematopoietic cells (38). 
Figure 5.11 shows that the ERK inhibitor PD98059 has no significant effect on 
NFkB activation by vGPCR. As a positive control to verify that the ERK inhibitor is 
effective in these cells, we also assayed its effect on vGPCR-mediated activation of 
AP-1; a process we have shown to be ERK dependent (38). Figures 5.8-5.11 allow 
us to expand the schematic shown in Figure 5.7 to that in Figure 5.12.
Given these data, we hypothesize that the broad signaling defect of the 
AITIM mutant is due to improper activation of Src, likely via poor G protein coupling. 
This may be due to conformational changes that the mutation confers. Investigating 
this hypothesis is beyond the scope of this thesis but will be the subject of future 
work.
SHP-2 has been associated with signaling via various growth factors and 
cytokines and with signal transduction processes such as the Ras-Raf-MAPK, JAK- 
STAT, PI3K, and NFkB pathways. However, other than the EGF receptor, the 
precise substrates for SHP-2 are not worked out and are so far identified only as
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Figure 5.9. AITIM mutant is less efficient at Src activation than 
wild-type vGPCR. HEK 293 cells were transfected with either 
control plasmid, vGPCR or AITIM mutant. 48 hours post-transfection 
lysates immunoprecipitated with anti-Src antibody. Immuno- 
complexes were then used in kinase assay in which Src activity is 
measured by its ability to self-phosphorylate in presence of radio- 
labeled ATP. Lysates were then run on 10% PAGE gel, fixed, dried, 
and exoosed.
Figure 5.10. SHP-2 is not required for KSHV vGPCR-mediated 
activation of ERK. HEK 293 cells were co-transfected with either 
vGPCR or control plasmid along with a-transducin subunit, Src 
dominant negative or SHP-2 dominant negative as shown. 48 hours 
post-transfection lysates were subjected to Western blotting with 
anti-phospho-ERK antibody. Blots were then stripped and re-probed 
for total ERK. Blot shown is representative of three independent 
experiments.
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Figure 5.11 vGPCR activation of NFkB is not ERK dependent. HEK
293 cells were transfected with control plasmid or vGPCR as shown. In 
addition NFkB (left panel) or AP-1 (right panel) luciferase reporter 
constructs were also transfected. All samples included TK-Renilla 
expression plasmid to control for transfection efficiency. 36 hours after 
transfection, the ERK inhibitor PD98059 (25 jim) was added where 
indicated. Cells were lysed after 48 hours and Luciferase assays 
performed. Results are normalized to control. Shown is average of two 
independent experiments. Bars indicate S.D.
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p90, p120, and p150 (173). Given that vGPCR activates both the MAP kinase and 
N F k B pathways, we used a SHP-2 dominant-negative substrate-trapping construct, 
SHP-2(c/s) (gift of Yehenew Agazie), to determine whether SHP-2 is necessary to 
either of these pathways. Figure 5.10 shows that SHP-2(c/s) did not inihibit 
vGPCR-mediated ERK phosphorylation. Furthermore, the luciferase reporter 
assays in Figure 5.13 show that SHP-2(c/s) actually enhanced both vGPCR- 
mediated N F k B and AP-1 activity. The cause for this increase is not clear. It is, 
however, not unexpected that inhibition by SHP-2(c/s) was not seen given our 
earlier experiments showing no vGPCR-induced increase in SHP-2 phosphatase 
activity. Moreover, these experiments cannot completely rule out a minor 
contribution of SHP-2 to vGPCR-mediated ERK activation, but do indicate that other 
vGPCR-induced events are either more potent or are recruited to activate ERK in 
the absence of SHP-2.
Src
ERK
AP-1 N F k B
Figure 5.12. Expanded schematic of vGPCR activation of 
Src, SHP-2, ERK, and the transcription factors AP-1 and 
NFk B.
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Figure 5.13. SHP-2 c/s, a dominant-negative mutant of 
SHP-2, does not interfere with vGPCR-induced NFkB or 
AP-1 activation. BC3.14 cells were transfected with the 
appropriate luciferase reporter construct with and without SHP- 
2 c/s. 48 hours post transfection cells were lysed and 
lucuferase assays performed. Shown is average of two 
independent experiments. Bars represent S.D.
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CHAPTER 6
6.0 Introduction
The TGFp superfamily members were discovered though their role in body plan 
development and tissue differentiation via effects on cell proliferation, differentiation 
and migration. They are also involved in control of extracellular matrix formation 
and immunosuppression (170). TGFp signaling is thought of as a linear pathway 
from the TGFp type I and type II receptors to SMAD activation, which results in the 
ligand-induced transcription associated with TGFp (126). The functional complex 
of the TGFp receptors consists of two type I and two type II transmembrane 
serine/threonine kinases receptors. Type I receptors have a Gly-Ser sequence 
upstream of the kinase domain that is phosphorylated by the type II receptor upon 
ligand binding. The type I receptor then phosphorylates one or more of the 
receptor-activated SMADs (R-SMADs). Combinatorial interactions in the receptor 
complex dictate ligand binding and differential signaling in response to a given 
ligand. A ligand, therefore, can induce different signaling pathways depending on 
the composition of the receptor complex (68). For example, TpRII can interact with 
TpRI resulting in activation of SMAD2 and SMAD3; when TpRII binds to ALK1, 
however, SMAD1 and SMAD5 are activated. Sometimes such differential signaling 
occurs within the same cells, making it very difficult to determine the overall effects 
of TGFp (107).
Once bound to ligand, the TpRI receptor phosphorylates the carboxy- 
terminus of the R-SMADs such as SMAD2 and SMAD3, which are released from
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the receptor complex to form a heterotrim eric complex comprising two R-SMADs 
and a common SMAD4. SMAD4 contains both nuclear localization signals and 
nuclear export signals which result in constant shuttling between cytoplasm and 
nucleus. The R-SMADs however, localize to the nucleus only after activation and 
association with SMAD4 (see Figure 6.1) (for review, see (69)). TGFp-mediated 
transcription is determined by the physical interaction and functional cooperation of 
the SMADs with sequence-specific transcription factors. SMAD affinity to DNA in 
itself is weak, but it is required for transcriptional activation. In addition to a large 
array of DNA-binding transcription factors, the R-SMADs interact with co-activators 
such as CBP/p300 as well as co-repressors. SMAD4 helps to stabilize the 
interaction of the R-SMADs with DNA and CBP/p300 (124).
TGFp generally has an inhibitory effect on cell growth; for example it inhibits 
c-myc and can activate the cyclin-dependent kinase inhibitors, thus stalling cell 
cycle progression (54). It can also inhibit differentiation in myoblasts, osteoblasts 
and adipocytes. Given its cytostatic effects, it is not surprising that dysregulation of 
the TGFp pathway has been noted in several malignancies: breast cancer, T cell 
lymphomas, colon cancer, and head and neck squamous cell cancer to name a few 
(95, 114, 130, 167, 262). Haematologic malignancies are associated with several 
different mechanisms of TGFp pathway interference at the receptor and SMAD 
levels. As mentioned in section 1.14, HTLV-1 Tax inhibits SMAD3/4 formation and 
SMAD3 DNA binding (182). In the case of chronic myeloid leukemia, EVI-1, a zinc- 
finger protooncogene, is overexpressed. The first zinc-finger domain of EVI-1 
associates with Smad3 and represses its transcriptional activity by recruiting histone
136
E x t r a c e l l u l a r  T PRI W L^ T P RI1
Cytoplasm
Smad7
Smad4
Smad2 Smad3
Nucleus
Sno/Ski 
HD AC
CBP/p300 
HAT
Target Genes
Figure 6.1. Schematic of TGFp signalling. TGFp binds to and activates the 
tetrameric TGFp receptor complex consisting if TpRI and TpRII. Activated TpRI 
phosphorylates Smad2 and Smad3 which then complex with Smad4 and 
translocate to nucleus. The Smad complex associates with other transcription 
factors and binds to target promoter. It regulates expression via HAT or HDAC 
Smad7 is a target of TGFp and downregulates its signalling by competing with 
Smad2 and Smad3 for TpRI binding.
Adapted from Li et al., (2006) Ann Rev Immunol 42:99-146
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Figure 6.1. Schem atic of TGFp signalling. TGFp binds to and activates the 
tetrameric TGFp receptor complex consisting if TpRI and TpRII. Activated TpRI 
phosphorylates Smad2 and Smad3 which then complex with Smad4 and 
translocate to nucleus. The Smad complex associates with other transcription 
factors and binds to target promoter. It regulates expression via HAT or HDAC 
Smad7 is a target of TGFp and downregulates its signalling by competing with 
Smad2 and Smad3 for TpRI binding.
Adapted from Li et al., (2006) Ann Rev Immunol 42:99-146
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deacetylase through CtBP that interacts with Evi-1 (145, 146). Acute myeloid 
leukemia is associated with dominant-negative mutations in SMAD4 and TpRI 
polymorphisms, while decreased SMAD3 production has been noted in childhood T- 
cell ALL (123, 207, 284). Various non-Hodgkins lymphomas (NHL) are noted to 
have decreased expression of TpRI or TpRII and in one case, a dominant negative 
mutation of TpRII (40, 138, 239).
CHAPTER 6: RESULTS
6.1 Transduction of TpRII into PEL cells results in SMAD2 phosphorylation 
by TGFP
KSHV infects B cells in vivo and gives rise to B cell lymphoproliferative disorders, 
including the rare non-Hodgkins lymphoma, PEL. We hypothesized that like other 
NHL, the TGFp pathway is dysregulated in PEL. Working simultaneously, the 
Cesarman lab at Cornell and I both found by RT-PCR that PEL cells contain no 
TpRII message (data not shown). When we realized we were working along the 
same lines, Dr. Cesarman and I decided to collaborate on this project. In her lab 
they have found that PEL cells do express the SMADs and that transient 
transfection of TpRII reconstitutes a transcriptional response to TGFp. Since B cells 
are difficult to transfect, phenotypic studies of PEL cells stably expressing TpRII 
required another approach. I therefore engineered a lentivirus expressing TpRII to 
transduce the PEL cell line BC3. Figure 6.2A shows that 48 hours after 
transduction, transduced BC3 cells express TpRII mRNA. Furthermore, this
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resulted in SMAD2 phosphorylation in response to TGFp (5 ng/ml) as demonstrated 
by the Western blot in 6.2B. Of note, there was a slight but reproducible increase in 
SMAD2 phosphorylation even in the absence of TGFp. This is consistent with the 
Cesarman lab’s data that PEL cells secrete TGFp into the surrounding medium 
(personal communication).
Using TGFp-responsive luciferase reporters, I next tested whether 
reconstitution of TpRII conveyed a transcriptional response to TGFp. The p3TP-lux 
construct (gift of J. Massague) is a commonly used TGFp reporter and the SBE4-luc 
(gift of Bert Vogelstein) is a similar construct containing 4 repeats of the SMAD- 
binding element. As seen in Figure 6.3A, increasing doses of TGFp increase 
transcription from p3TP-lux construct in TpRII-transduced BC3 cells (top panel) 
whereas control cells do not respond to even the highest TGFp dose used (bottom 
panel). Results were not as pronounced for SBE4-luc (Fig. 6.3B), but they also 
support the idea that it is the lack of TpRII that renders PEL cells unresponsive to 
TGFp.
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Figure 6.2. Lentiviral transdution of BC3 cells reconstitutes 
phosphorylation of SMAD2 in presence of TGFp . BC3 cells were 
transduced with lenti-TpRII at 5 copies per host cell genome. (A) 48 
hours post-transduction, mRNA was isolated and RT-PCR performed 
using primers for both GAPDH and TpRII. Samples without prior RT 
were also subjected to PCR as control for DNA contamination of mRNA 
samples. (B) BC3 cells with and without lenti-TpRII transduction were 
stimulated overnight with TGFp (5ng/ml) where indicated. Western 
blotting for phosphorylated SMAD2 was then performed on protein 
lysates. Blots were stripped and re-probed for p-actin as a loading 
control.
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Figure 6.3. Lentiviral transduction of TGFpRII into BC3 cells reconstitutes 
transcriptional response to TGFp. (A) Top Panel, BC3 cells were transduced 
with lenti-TGFpRII. 24  hours later they were transfected with the TGFp  
luciferase reporter construct p3TP-lux. 24 hours post-transfection cells were 
exposed to TGFp at doses shown. Luciferase assays were performed 17 hours 
later. Lower Panel, BC3 cells transduced with lenti-GFP were transfected with 
p3TP-lux, exposed to maximum dose of TGFp, and luciferase assays performed 
as above. (B) BC3 cells transduced with lentivirus expressing either GFP or 
TGFpRII were transfected with luciferase reporter SBE4-Luc, exposed to TGFp  
and subjected to luciferase assays as in (A). Shown are the averages of two 
experiments each done in triplicate. Results were normalized to control. Bars 
represent S.D.
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6.2 Expression of TRpil in PEL cells leads to apoptosis
To ascertain whether reconstituting a transcriptional respose to TGFp leads to 
TGFp-induced apoptosis in PEL cells, annexin V staining was performed on parent 
BC3 cells and TRpll-transduced cells. Although just a pilot study, Figure 6.4 shows 
that TRpll-transduced cells are indeed susceptible to TGFp-induced apoptosis. 
Studies are ongoing to establish a dose-response effect and will also incorporate 
neutralizing anti-TGFp antibody to verify that the effect seen is due to TGFp.
2.5
CD
i 1 <
0.5 
0
Figure 6.4 Expression o f TRpil in PEL cells leads to  
apoptosis. BC3 cells were transduced with lenti-TRpll or empty 
lenti vector as control. After 24 hours, cells were exposed to 1 
ng/ml TGFp. 48 hours later annexin V staining was done and 
quantified by flow cytometry.
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6.3 The KSHV vGPCR upregulates transcription via TGFp-responsive 
promoters.
The KSHV vGPCR signals via diverse pathways, and as seen in Chapter 3, it 
upregulates p21 thereby causing cell cycle arrest in PEL cells. Using the p3TP-lux 
and SBE4-luc reporters shown in Figure 6.3, we tested whether vGPCR could 
activate a TGFp-responsive signaling pathway since it too upregulates p21. Figure
6.5 shows that vGPCR increases transcription via both reporters in a dose- 
dependent manner. To verify specificity of the response, the vGPCR agonist Groa 
and the inverse agonist, IP-10 were included in the experiment. As would be 
expected, GROa enhanced the vGPCR effect while IP-10 inhibited it. Neither 
chemokine had a significant effect in the absence of vGPCR expression. This is a 
very recent finding, and how vGPCR interacts with the SMAD transcription factors 
will be the subject of future research. For example, it remains to be established 
whether vGPCR-mediated induction of p21 is via the same cascade as TGFp. Why 
KSHV would evolve to suppress TpRII and thus the normal TGFp pathway, while 
encoding its own viral product that can mimic TGFp will be discussed in Chapter 7.
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Figure 6.5. KSHV vGPCR activates transcription via TGF0-responsive 
promoters in PEL cells. BC3 cells were transfected with either SBE4-luc (A), 
or p3TP-lux (B) and then exposed to doses of doxycycline as shown to induce 
expression of KSHV vGPCR. 24 hours post-transfection, the vGPCR agonist 
Grou or the inverse agonist IP-10 were added (100nM). 48 hours post­
transfection, lysates were made and luciferase assays performed. Shown are 
averages of two independent experiments. Bars represent S.D.
144
CHAPTER 7: DISCUSSION
7.1 vGPCR-mediated effects on cell cycle and viral replication
KSHV vGPCR signaling and function have been assayed in several cell types, but 
few studies have been done in hematopoietic cells. KSHV-infected hematopoietic 
cells are a vital source of new virion production in all KSHV-mediated disease. 
Furthermore, ongoing virion production is essential to maintain KSHV-derived 
tumors. For that reason we studied vGPCR signaling, transcription factor activation 
and phenotypic effect in PEL cells (KSHV-infected lymphoma cells of B cell 
lineage). Our initial studies showed that overexpression of vGPCR results in 
decreased proliferation (37). This finding was surprising since vGPCR had already 
been classified as a viral oncogene that transforms fibroblasts and endothelial cells. 
We also noted that when overexpressed in uninduced, latently infected cells, 
vGPCR modestly increases the transcription of ORF 50 and ORF 57. Since cell 
cycle manipulation and lytic gene product expression are intimately connected in 
herpesvirus replication, we sought to better understand the mechanism of vGPCR- 
induced cell cycle arrest and its effect on lytic gene transcription in KSHV.
Using standard techniques we show that vGPCR signaling results in growth 
arrest, likely at multiple points throughout the cell cycle. It has been shown that 
ERK-1/2 and p38 can act in concert to cause a p53-independent, p21-mediated G1 
arrest (270). Furthermore, we have previously shown that in PEL cells, vGPCR 
induces both ERK 1/2 and p38 activity (37). We therefore hypothesized that p21 
was the CDI primarily responsible for vGPCR-induced arrest. Our data here
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support such a signaling pathway in PEL cells. Consistent with activation of p21, 
we show that the S-phase kinase Cdk2 is markedly inhibited by vGPCR. Although 
cell cycle arrest generally coincides with herpesviral latent-lytic switch, Cdk2 activity 
remains essential for replication (83). Using lytic gene transcription as a surrogate 
for successful replication, our data strongly support a vGPCR-driven inhibition of 
viral replication via downregulation of Cdk2. It remains possible however, that there 
are additional vGPCR-mediated events that also contribute to cell cycle arrest or 
lytic phase inhibition. For example, it has been shown many times that vGPCR 
induces NFkB activity; and NFkB has in turn been shown to inhibit the KSHV lytic 
activation (32).
Several studies support the idea that vGPCR may be expressed outside the 
context of the KSHV lytic cycle. HIV Tat increases the expression of vGPCR and 
recent work from the Ganem lab showed that vGPCR may be regulated by RBP-Jk , 
a transcription factor and target of the Notch pathway (158, 292). Furthermore, 
abortive lytic cycle progression in which a subset of lytic genes products is 
expressed has been shown in other herpesviruses. If such deregulated expression 
of vGPCR does occur, our data have implications for a longstanding conundrum in 
the vGPCR literature: as a lytic gene, it is difficult to reconcile either a directly 
transforming role, or indeed a paracrine role for vGPCR despite the many KS- 
related cytokines elaborated as a result of its signaling. Presumably a lytically 
activated KSHV-infected cell that is expressing vGPCR is destined to die and 
therefore not able to sustain a prolonged paracrine effect on surrounding cells. If, 
however, a sustained upregulation of vGPCR were to occur prior to a latent-lytic
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switch, vGPCR may delay or even prevent full lytic transcription and cell death. 
Consequently, the proliferative and angiogenic potential of vGPCR would have time 
to be biologically significant in the tumor microenvironment. Furthermore, vGPCR- 
driven recruitment of new infectible cells would ensure viral propagation, producing 
as a byproduct the abnormal cellular proliferation characteristic of KSHV-mediated 
tumors (Figure 7.1). So although it may be that a few short-lived lytically activated 
cells can have an effect on the tumor microenvironment, the potential of a vGPCR- 
induced prolongation of an aberrant lytic phase exists and requires further 
investigation. The potential effects of a dysregulated (i.e. non-lytically expressed) 
vGPCR has been described in a recent review by Sodhi et al (251).
Aside from possible dysregulated expression outside the lytic cycle, the 
‘normal’ lytic expression of vGPCR may also play a significant role in KSHV 
replication. KSHV has evolved mechanisms to carefully regulate vGPCR. Its 
expression is restricted in that it is transcribed within the 3’ end of a bicistronic 
message; furthermore, KSHV encodes vCLL2, an inverse agonist of vGPCR (267). 
Precise control of vGPCR signaling suggests that the timing and level of vGPCR 
signaling is crucial to KSHV propagation and it is likely that vGPCR plays more than 
one role in course of KSHV-mediated disease. This may explain why we have 
previously found that in the setting of latent infection, vGPCR overexpression 
results in modest increased ORF 50 activity (37), but in the setting of lytic induction, 
vGPCR downwardly modulates the transcription of ORF 50. An interesting finding 
by Dezube et. al. is that during early de novo KSHV infection of primary endothelial 
cells, vGPCR transcription fluctuates in a cyclic pattern with a 48 to 72-hour time
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course consistent with viral replication (70). vGPCR-induced changes in viral 
transcription patterns or in host cell function (including cell cycle) may be required 
during initial infection to establish successful latency or perhaps to kick start the 
initial rounds of lytic replication. Whether the cyclic pattern of vGPCR transcription 
is specific to endothelial cells remains to be studied.
We have established the ability of vGPCR to mediate cell cycle arrest of 
infected B cells and provide compelling evidence that this occurs via Cdk2 
inhibition. Furthermore, we provide initial evidence that this results in abnormal lytic 
phase induction. Independent inhibition of Cdk2 suggests that as with other 
herpesviruses, this kinase is required for normal KSHV lytic gene induction. 
Although this helps explain how a lytic gene product could have important paracrine 
effects on surrounding cells, there remain questions about the exact role of vGPCR 
in the establishment of KSHV infection, maintenance of latency, and the latent to 
lytic switch. Our novel findings presented here are currently being extended to 
determine how vGPCR expression affects the quantity and infectivity of new virions. 
Furthermore, vGPCR-mediated effects on other KSHV lytic genes are being 
investigated and will shed light on the remaining questions about this pirated 
chemokine receptor and its potential as a target of rationally designed anti-KSHV 
treatment.
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Figure 7.1. Schematic of vGPCR function. Extracellular and intracellular 
factors both upregulate vGPCR signalling which results in cell cycle arrest with 
inhibition of viral replication and cell death. This allows more prolonged effect of 
vGPCR on surrounding cells than would otherwise be possible if the lytic 
replication phase were to occur unhindered.
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7.2 Targeting the PTP pathway
Given that vGPCR is a homologue of human GPCRs, it could be argued that 
rational therapeutic design to inhibit vGPCR would be unlikely to result in a suitably 
specific ligand that does not interfere with normal GPCR function. This is a very 
reasonable argument and so it remains important to discover as much as we can 
about what role vGPCR plays in different KSHV-infected cell types and which of its 
many downstream signaling pathways are responsible for these roles. Such 
knowledge would allow us to direct therapeutic design at specific downstream 
vGPCR-mediated events. That approach combined with targeted delivery systems 
would go a long way to achieving acceptable therapeutic indices for novel agents. 
For these reasons, we extened our search for vGPCR signaling intermediates 
beyond what was already published. Chapter 5 of this thesis shows some of our 
initial findings regarding vGPCR and the cytoplasmic PTPs.
The cytoplasmic PTPs, SHP-1 and SHP-2, are involved in signaling via many 
growth factors and are essential to proper cell proliferation and differentiation. As a 
testament to their importance, human pathogens from bacteria to protozoa, to 
viruses have evolved to dysregulate PTP activity: Helicobacter pylori activates 
SHP-2 which in turn dephosphorylates focal adhesion kinase and produces the 
‘hummingbird’ cell shape in gastric epithelial cells (271). Leishmania species 
interfere with macrophage function and the host immune response by activating 
SHP-1 (190, 191). HTLV-1 transformed cells have lost SHP-1 activity as have 
various lymphomas and leukemias (200) (174). Furthermore, overexpression of 
SHP-2 has been linked to leukemogenesis in humans (290).
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Given the strong association of dysregulated PTP function with lymphoma 
and the known interaction of several GPCRs with the PTPs, we hypothesized that 
the KSHV vGPCR interacts with this vital signaling pathway. We found that 
although the consensus ITIM sequence in vGPCR does not result in activation of 
SHP-2 phosphatase activity, SHP-2 is phosphorylated by vGPCR at its carboxy 
terminus in a Gaq/Src-dependent manner in HEK 293 cells. A lack of vGPCR- 
induced SHP-2 phosphatase activity does not mean, however, that SHP-2 is not 
important to vGPCR signaling. As discussed above, SHP-1 and SHP-2 are thought 
to have important scaffolding functions aside from their catalytic activity. There are 
various receptors which associate with SHP-1 and SHP-2 but do not activate their 
phosphatase activity. Studies are ongoing to determine whether the increased 
carboxy phosphorylation of SHP-2 results in increased association with Gab1, 
Gab2, and Grb2, all signaling intermediates capable of binding to SHP-2.
Our experiments so far with SHP-2 have been done in HEK 293 cells. Future 
work will consist of lentiviral transduction of vGPCR into primary cell types more 
relevant to KSHV -m ediated disease. For example, primary lymphatic endothelial 
cells (LEC) can be cultured and manipulated in vitro and transduction efficiencies of 
greater than 50% are achievable with HIV-based lentiviral vectors. Furthermore, 
both KSHV-infected B cell lines and primary B cells can be readily transduced so 
that we will be able to determine if vGPCR has the same effects on SHP-2 as we 
have seen in HEK 293 cells.
Since SHP-1 is expressed predominantly in B cells, we will determine 
whether KSHV-infected B cells express SHP-1 and if so how vGPCR affects its
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binding and/or scaffolding functions. We have very preliminary data that show 
vGPCR downregulates SHP-1 phosphatase activity (data not shown). As 
mentioned above, inhibition of SHP-1 expression and/or function is a common event 
in human lymphomas. It is still unclear whether down-regulation of SHP-1 is itself 
required for lymphomagenesis or whether low levels of SHP-1 merely reflect the 
physiologic regulation associated with the immaturity of the neoplastic cells.
Clearly, such a conserved mechanism of cell growth dyregulation in haematopoietic 
malignancies deserves further scrutiny in KSHV-associated lymphoproliferative 
diseases. It is possible that KSHV requires vGPCR to inhibit SHP-1 at certain times 
in the process of viral replication or perhaps to give a growth advantage to KSHV- 
infected B cells that are mature enough to be expressing SHP-1. Luckily, both gain 
and loss-of-function mutants are available for SHP-1 and SHP-2 and will facilitate 
exploring how vGPCR manipulates the PTPs and which downstream vGPCR 
events rely on that manipulation. Only then can we determine if interfering with 
vGPCR-induced changes in PTP function is a feasible anti-KSHV strategy.
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7.3 Dysregulation of TGFp pathway in KSHV-mediated disease
The pathogenesis and treatment of haematopoietic malignancies differs somewhat 
from that of solid tumours. The former are more associated with aging whereas the 
latter affect a broad age range. Of course similarities exist and include the ability to 
resist growth-inhibitory and differentiation factors, growth in the absence of 
exogenous growth signals, evasion of apoptosis, and the evasion of immune 
surveillance. The TGFp pathway is an example of a homeostatic mechanism that is 
frequently disrupted in haematopoietic malignancies. We therefore sought to 
establish whether such is the case in PEL, one of the KSHV-mediated 
lymphoproliferative diseases.
Together with the Cesarman lab at Cornell, we found that none of the PEL 
lines tested express TpRII and therefore cannot signal in response to TGFp. In this 
thesis I used lentiviral transduction to reconstitute TpRII expression and show that 
in transduced cells, TGFp leads to SMAD2 phosphorylation whereas the 
untransduced cells show none. Using luciferase reporter constructs I also show 
that transduction of TpRII leads to transcriptional activation of TGFp and SMAD- 
responsive genes in response to TGFp. Together these results strongly suggest 
that other than the TpRII, the components of the TGFp pathway are intact in PEL 
cells. Furthermore, the Cesarman lab has confirmed the expression of the SMADs 
by rt-PCR (personal communication). To test whether transduction of TRpil leads 
to a phenotypic response to TGFp, I have begun apoptosis assays in which parent 
BC3 cells and TRpil-transduced BC3 cells are compared in their apoptotic response
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to TGFp as evidenced by annexin V staining. Although these experiments are still 
underway, the pilot study suggests that this is the case. The experiment is being 
optimized and eventually will be performed with escalating doses of TGFp as well 
as neutralizing anti-TGFp antibody to ensure that any differences between 
transduced and untransduced cells are specifically due to TGFp.
As noted in Chapter 6, it appears that PEL cells secrete TGFp into their 
surrounding medium. This fact combined with our findings that PEL cells are 
unresponsive to TGFp suggests that KSHV has evolved a survival strategy that can 
potentially confer a growth advantage to infected haematopoietic cells while 
inhibiting the host immune response. Since TGFp is homeostatic for most cells of 
haematopoietic lineage, KSHV-infected B cells need to be resistent to its effects. 
Furthermore, since some degree of KSHV replication is always ongoing, the virus 
has needed to evolve varied and potent immune evasion strategies. It is highly 
plausible that by secreting TGFp, KSHV-infected cells discourage the proliferation 
and differentiation of local host immune cells.
Future work will include using a well established mouse model of PEL in 
which intraperitoneal injection of PEL cells results in gross ascites (133). Using this 
model, lentiviral transduction of TpRII can be assessed for its effect on PEL 
development as determined by serial girth measurements. Such experiments could 
further support the hypothesis that downregulation of TpRII is a potent survival 
mechanism in KSHV-induced lymphoproliferative disease.
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As presented in Figure 6.5 we have found that KSHV vGPCR may share 
some downstream effectors with the TGFp pathway. vGPCR transfection into PEL 
cells activates both TGFp- and SMAD-responsive promoters. Whether vGPCR 
uses the same mechanism as TGFp to upregulate p21 (see Chapter 3) remains to 
be seen. Furthermore, we and others have shown that vGPCR upregulates the 
secretion of both human IL-6 and viral IL-6 from various haematopoietic cell lines. 
TGFp and IL-6 together are known to have effects on T cell differentiation. For 
example, the TGFp elaborated by Treg cells along with IL-6 subvert Th1 and Th2 
development in favor of the proinflammatory IL-17 secreting T17 cells (275, 276). 
Whether vGCPR is involved in subverting the immune response has not been 
properly investigated but our new data have prompted us to characterize the 
potential autocrine and paracrine effects of vGPCR on T cell differentiation. 
Autocrine effects can be studied using lentiviral transduction of vGPCR; paracrine 
effects using the conditioned medium of PEL cells +/- overexpression of vGPCR will 
also be studied. Chemokine receptors help co-ordinate both the innate and 
adaptive immune responses, so further study of vGPCR in this context is likely to 
very informative.
155
7.4 Conclusions
During its evolution, KSHV has pirated several genes from its primate hosts. These 
have generally undergone mutation, presumably conferring a proliferative 
advantage to the virus. In the case of vGPCR, the advantages appear to be many. 
We know that vGPCR expression confers both an autocrine and paracrine growth 
advantage to endothelial cells. Furthermore, expression in haematopoietic cells 
results in the elaboration of many cytokines that have long been associated with 
KSHV-mediated diseases. In this thesis we have presented evidence that vGPCR 
also has a negative effect on host cell cycle which in turn inhibits viral production 
from B cell reservoirs. We hypothesize that this inhibition of virion production may 
lend additional potency to the paracrine effects of vGPCR by creating a population 
of infected cells that secrete cytokines required for angiogenesis and recruitment of 
infectable cells necessary to viral reproduction. Since vGPCR is a chemokine 
receptor it is also likely that it has an effect on the host immune response. Our 
preliminary data showing that vGPCR can mimic TGFp signaling in reporter assays 
supports this notion and requires further study.
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